Proteogenomics Reveals how Metastatic Melanoma Modulates the Immune System to Allow Immune Evasion


Jeovanis Gil^{1,16,*}, Yonghyo Kim^{1,16}, Beáta Szeitz^{2,16}, Viktória Doma^{3,4}, Uğur Çakır³, Natália Pinto de Almeida^{5,6}, Yanick Paco Hagemeijer^{7,8}, Victor Guryev⁷, Jenny G Johansson⁹, Yogita Sharma⁹, Indira Pla Parada¹⁰, Zsolt Horvath⁵, Jéssica de Siqueira Guedes⁶, Gustavo Monnerat⁶, Gabriel Reis Alves Carneiro⁶, Fábio CS Nogueira⁶, Boram Lee¹, Henriett Oskolas¹, Enikő Kuroli³, Judit Hársing³, Yutaka Sugihara¹, Magdalena Kuras¹⁰, Roger Appelqvist¹, Elisabet Wieslander¹, Gilberto B Domont⁶, Bo Baldetorp¹, Runyu Hong¹¹, Gergely Huszty¹², Laura Vizkeleti⁴, József Tímár⁴, David Fenyö¹¹, Lazaro Hiram Betancourt¹, Johan Jakobsson⁹, Johan Malm¹⁰, Aniel Sanchez¹⁰, A. Marcell Szász^{2,13}, Peter Horvatovich⁸, Melinda Rezeli⁵, Sarolta Kárpáti^{3,17}, and György Marko-Varga^{5,14,15,17}

- ¹⁻ Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
- ²⁻ Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
- ³⁻ Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
- ⁴⁻ Second Department of Pathology, Semmelweis University, Budapest, Hungary
- ⁵⁻ Clinical Protein Science & Imaging, Department of Biomedical Engineering, Lund University, Lund, Sweden
- ⁶⁻ Chemistry Institute, Federal University of Rio de Janeiro, **Rio de Janeiro, Brazil**
- ⁷⁻ European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- ⁸⁻ Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
- ⁹⁻ Laboratory of Molecular Neurogenetics, Department of Experimental Medical Science, Lund University, Lund, Sweden
- ¹⁰⁻ Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden
- ¹¹⁻ Institute for Systems Genetics and Department of Biochemistry and Pharmacology, New York University, Grossman School of Medicine, **New York, USA**
- ¹²⁻ Department of Transplantation and Surgery, Semmelweis University, **Budapest, Hungary**
- ¹³⁻ Department of Bioinformatics, Semmelweis University, Budapest, Hungary
- ¹⁴⁻ Chemical Genomics Global Research Lab, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, **Seoul, Republic of Korea**
- ¹⁵⁻ 1st Department of Surgery, Tokyo Medical University, **Tokyo, Japan**
- ¹⁶⁻ These authors contributed equally
- ¹⁷⁻ Senior author

* correspondence: jeovanis.gil valdes@med.lu.se (Jeovanis Gil)

Gil J. et al. | Malignant melanoma proteogenomics

TOC figure:



Gil J. et al. | Malignant melanoma proteogenomics

Summary:

Malignant melanoma (MM) develops from the melanocytes and in its advanced stage is the most aggressive type of skin cancer. Here we report a comprehensive analysis on a prospective cohort study, including non-tumor, primary and metastasis tissues (n=77) with the corresponding plasma samples (n=56) from patients with malignant melanoma. The tumors and surrounding tissues were characterized with a combination of high-throughput analyses including quantitative proteomics, phosphoproteomics, acetylomics, and whole exome sequencing (WES) combined with in-depth histopathology analysis. Melanoma cell proliferation highly correlates with dysregulation at the proteome, at the posttranslational- and at the transcriptome level. Some of the changes were also verified in the plasma proteome. The metabolic reprogramming in melanoma includes upregulation of the glycolysis and the oxidative phosphorylation, and an increase in glutamine consumption, while downregulated proteins involved in the degradation of amino acids, fatty acids, and the extracellular matrix (ECM) receptor interaction. The pathways most dysregulated in MM including the MAP kinases-, the PI3K-AKT signaling, and the calcium homeostasis, are among the most affected by mutations, thus, dysregulation in these pathways can be manifested as drivers in melanoma development and progression.

The phosphoproteome analysis combined with target-based prediction mapped 75% of the human kinome. Melanoma cell proliferation was driven by two key factors: i) metabolic reprogramming leading to upregulation of the glycolysis and oxidative phosphorylation, supported by HIF-1 signaling pathway and mitochondrial translation; and ii) a dysregulation of the immune system response, which was mirrored by immune system processes in the plasma proteome. Regulation of the melanoma acetylome and expression of deacetylase enzymes discriminated between groups based on tissue origin and proliferation, indicating a way to guide the successful use of HDAC inhibitors in melanoma. The disease progression toward metastasis is driven by the downregulation of the immune system response, including MHC class I and II, which allows tumors to evade immune surveillance. Altogether, new evidence is provided at different molecular levels to allow improved understanding of the melanoma progression, ultimately contributing to better treatment strategies.

Keywords:

melanoma, proteogenomics, phosphoproteomics, lysine acetylation, evasion of immune surveillance, metabolic reprogramming, MHC class I, MHC class II, tumor proliferation

1. Introduction

Among the skin cancers, malignant melanoma is the deadliest, and its incidence and mortality are rising, particularly in Europe ^{1,2}. However, the early surgical intervention, and more recently the advent of targeted therapy and immunotherapy have substantially improved the mortality rate of the disease. Melanoma is one of the most heterogeneous cancers at the genomic level, which results in a variety of distinct phenotypes of the disease ³. The high level of heterogeneity in melanoma has been previously linked to disease progression and short survival ^{4,5}. Additionally, the levels of mutated proteins and dysregulation of their biological pathways, critically impact the tumor biology and survival ⁶. Signaling pathways such as the PI3K-AKT, mTOR, and MAPK are usually dysregulated in melanoma. BRAF, which is a kinase involved in the MAPK/ERK signaling pathway is the most frequently observed driver mutation in melanoma counting for approximately 50% of cases ⁷. Thus, a common treatment strategy to target this pathway is to use a combination of BRAF and MEK inhibitors. After a progression free period, however, most of the responsive patients in stage 4 of the disease develop resistance to treatment and ultimately die.

Large cohorts of melanoma samples have been studied through genomics, transcriptomics, proteomics in attempts to decipher the molecular mechanisms driving the development and progression of the disease ^{8,9}. Phosphoproteomics and acetylomics on melanoma have shown dysregulation during the progression of the disease at the posttranslational level ^{10,11}. Additionally, a recent international milestone was reported; the high-stringency blueprint of the human proteome ¹², mapping the expression and functional annotation of the coded genome. In an attempt to integrate several high-throughput analyses into the biological understanding of the development and progression of melanoma, we performed a comprehensive multi-omic analysis including proteomics, PTM profiling, metabolomics, and whole-exome sequencing of 77 tissue samples coming from 47 melanoma patients, supplemented by the proteomic analysis of 56 plasma samples. The metabolic changes that take place during the development and progression of the disease were traced at different molecular levels. We demonstrated that the characterization of melanoma in such an integrative manner at different molecular levels led to a better biological understanding of the disease that will ultimately help to advance future therapeutic interventions

2. Results

2.1. Characteristics of the melanoma-related prospective cohort study

A cohort of 77 solid tissues, and 56 blood samples, originating from 47 different melanoma patients, enrolled in a prospective study, were submitted to a multi-omic analysis. Fresh frozen

Gil J. et al. | Malignant melanoma proteogenomics

biopsies originated from different organs and body localizations, including non-tumors (NT; >2 cm from the tumor edges; n=11), tumor microenvironments (TM; tumor edge without countable tumor cells; n=6), primary tumors (PT; n=16), local recurrences (LR; n=6), cutaneous metastases (CM; n=10), regional lymph node metastases (LN; n=23), and distant metastases (DM; coming from gallbladder, brain, liver, spleen, and breast; n=5) (Figure 1A). Blood sampling was performed prior to the surgical isolation of the tumor tissues. The relevant clinical information of the patients included in the study is presented in Table S1. All samples were submitted to quantitative proteomics. Besides, the tissue samples were subjected to quantitative phosphoproteomics and lysine acetylation stoichiometry analysis (Figure 1B). Complementary whole-exome sequencing (WES) was performed on the tumor tissue samples (60). The disease presentation within the tumors from the patients is outlined in Figure 1C, where grading was made according to the immune competence, as well as the tumor burden encompassing the metastasis types, the primary and non-tumors.




Figure 1. Melanoma-related cohort submitted to multi-omics approach. A) Tissue samples originated from non-tumor (green, n=11), tumor microenvironment (purple, n=6), primary tumor (n=16), local recurrence (orange, n=6), cutaneous metastasis (n=10), lymph node metastases (n=23), and distant metastasis (n=5). B) Workflow for the global proteomics, phosphoproteomics, and acetylomics used in tissue-derived samples. Tissue samples were sectioned (10 μ M thickness), sonicated using Bioruptor plus in SDS containing buffer. The proteins were acetylated with N-

Gil J. et al. | Malignant melanoma proteogenomics

acetoxysuccinimide-d3 (NAS-d3), followed by trypsin digestion. Generated peptides were divided into three different analyses; one fraction was directly injected onto LC-MS/MS system and analyzed following a data-independent analysis (DIA) method. A second fraction was submitted to an automated phosphopeptide enrichment analysis before LC-MS/MS analysis in a classical DDA method. The third fraction was measured following a DDA method without additional processing. Global proteomics data were analyzed with Spectronaut software, phosphoproteomics data was processed with Proteome Discoverer and acetylomics data by the combination of Proteome Discoverer and Pview. **C)** Spectrum of tumor-immune system imbalance is depicted during the progression of the disease. Starting from a relatively competent immunologic state both in peritumoral and intratumoral regions of low tumor load the pathological process ultimately results in high tumor burden with an exhausted immune system. Greyscale images correspond to the color figures above displaying areas of tumor (T), lymphoid infiltrate (L), and stroma (S). Oftentimes, this latter microenvironment adjacent to actual tumor cell nests is also dark (macroscopically), contains macrophages performing melanin phagocytosis.

2.2. Dysregulated pathways in melanoma carry a large mutation load

The tumor tissue samples were submitted to whole-exome sequencing (WES) analysis. In the absence of normal tissues as control, we relied on the gnomAD database's non The Cancer Genome Atlas (TCGA) subset of ExAC release 1 to estimate the "population background". The analysis revealed that melanoma does carry a higher number of somatic mutations, as compared to germline mutations (A>T and T>A SNP mutations, and indels are 15 and 224 times more abundant). However, the variants corresponding to SNP changes; A>G and T>C, were found to be underrepresented, whereas C>T and G>A were at comparable levels in somatic compared to germline mutations (Table S2). The relative ratio of different equivalent base-pair changes in somatic and germline SNPs variants are consistent across samples and the somatic patterns are different from the germline one. Germline patterns show high similarity with the population background except for A>G and T>C mutations, which is considerably larger in the germline pattern of the analyzed tumors compared to the population background (Figure S1A-B). The ratio of indels and SNPs in somatic mutations is substantially lower than in germline variants (0.81±0.03 and 74.53±4.48 SNPs/indels ratio respectively), indicating that melanoma is driven by indels rather than SNPs (Figure 2D). Differences in this ratio were not observable, based on the sample origin. We also found that indels are slightly extending exon and protein sequences in somatic variants, while germline indels tend to mainly shorten them (Figure S2). The highly reproducible somatic patterns suggest that mutations in melanoma are driven by similar underlying molecular mechanisms across all patients.

The high genetic heterogeneity of melanoma tumors was highlighted by lower sequence coverage of somatic compared to germline variants. While germline mutations are expected to be present in all cells, somatic mutations are only present in tumor cells, and different clones carry different somatic mutations (Figure S3). We performed hot spot analysis to identify the genes most frequently found carrying somatic mutations across the samples using a Chi-squared test followed by a multiple testing with Bonferroni correction. We were able to locate the chromosomal regions with somatic mutation burden (Figure S4). Genes that were significantly mutated in at least one-third of the samples (20 out of 60) were selected as hot spots (132 genes in total) (Figure 2A, Table S3). The functional annotation analysis revealed that to a large extent, these genes are involved in the interaction and regulation of the immune system (Figure 2B). Particularly, the genes coding for the protein elements of both MHC complexes class I and II carry mutations in most melanoma samples. To a lesser extent, genes functionally related to metabolism and signaling cascades were also among the most mutated genes.

The most dysregulated pathways in melanoma found in this study at the transcriptional, translational, and posttranslational level, were also found to carry a significantly higher level of both germline and somatic mutations than the background population (**Figure 2C, Table S4**). In this sense, the pathways most affected by mutations in melanoma are the signaling cascades including MAP kinases and PI3K-AKT, and the calcium homeostasis. Not surprisingly, dysregulations of these pathways have been considered drivers in melanoma development and progression. On average, these pathways carry at least 11 times more somatic than germline mutations, which indicates that the genes of these pathways are heavily affected by the mutation burden in melanoma.

Gil J. et al. | Malignant melanoma proteogenomics




Figure 2. Most mutated genes in melanoma are involved in the regulation of the immune system. A) List of genes identified as hot spots in at least one-third (20 samples out of 60) of the tumor cohort. B) Protein-protein interaction network of the hot spot genes. Highlighted in red are the protein elements of the complexes MHC class I and II, and in blue additional proteins involved in processes related to the regulation of the immune system. C) Violin plots showing the number of somatic (left axis) and germline (right axis) mutations in genes involved in 16 KEGG pathways known to play crucial roles and found dysregulated in melanoma. The numbers inside the graph represent the number of mutations in the pathway and the

Gil J. et al. | Malignant melanoma proteogenomics

percentage indicates the total number of genes detected in WES data relative to the total number of genes in the pathway. Data with the summary of the figure are outlined in **Table S4**. **D**) Number of mutations (indels vs. SNPs) for somatic and germline mutations in each sample on a logarithmic scale. Zoomed-in regions for somatic and germline mutations are shown.

2.3. Proteome profiling of biopsies from melanoma patients

Tissue samples were submitted to a workflow that allows, from the same sample processing, to perform quantitative proteomic. phosphoproteomic, and lysine acetylation stoichiometry analysis ^{10,13} (Figure 1B). Briefly, the frozen tissue was sliced, and 15 consecutive slices were used for proteomics and PTMs analysis, or whole-exome sequencing. The first and last slices were H&E stained for computing the sample composition (tumor, stroma, and immune cell content). Proteins extracted, followed by chemically acetylated with NAS-d3 and digested with trypsin. Generated peptides were delimited by arginine residues. For global proteomics, peptides were directly analyzed by highresolution mass spectrometry following a data-independent analysis (DIA) method. The phosphoproteome analysis included an automated phosphopeptide enrichment step using IMAC (Fe(III)-NTA), followed by high-resolution mass spectrometry data-dependent analysis (DDA). For lysine acetylation stoichiometry analysis, peptides were analyzed following a DDA method for acquisition (Figure 1B).

The proteomic analysis resulted in the identification and quantification of 9040 proteins with more than 2500 identified in all analyzed samples (**Figure 3**). On average, we identified approximately 7000 proteins in the tumor samples. 17237

phosphorylated peptides were identified in phosphoproteomics data, approximately 8000 in each sample. Additionally, we identified and determined the site-specific occupancy of 6844 acetylated peptides in at least 3 different samples, which correspond to 3024 different proteins. The plasma proteome analysis of the patients resulted in the identification of 1370 proteins.

From the proteomic data, the relative abundance profiles of the protein elements of the minichromosome maintenance (MCM) complex were extracted and submitted to hierarchical clustering analysis. As a resulting outcome, all samples were grouped into four groups from lower to higher levels of the complex elements (Figure 3). MCM is a hetero-hexameric complex required for DNA replication, which possesses DNA helicase activity ^{14–17}. Due to its role in DNA replication and because their protein elements have been reported as proliferation markers and associated with progression in many cancers ^{14,15,25,26,16,18–24}, we procured their protein abundance profiles as a measure of the proliferation-rate of the sample. The levels of the well-known proliferation marker Ki-67 showed significant differences between the proliferation groups, where the groups with higher MCM complex levels, also upregulate Ki-67 (Figure 3). As expected, non-tumor and tumor microenvironment samples were grouped in the low proliferative groups and Ki-67 was not detectable in any of them.

Gil J. et al. | Malignant melanoma proteogenomics




Figure 3. Proteomics of fresh frozen tissue biopsies from melanoma patients. A total of 77 samples coming from 47 different patients are grouped according to their origin. Eleven Non-tumor (NT) biopsies from more than 2 cm from the tumor boundaries, six tumor microenvironment (TM) samples taken from the tumor edges without the presence of tumor cells, sixteen biopsies from primary tumors (PT), six biopsies from local recurrence (LR) of the disease, ten biopsies of cutaneous metastases (CM), twenty-three metastases in regional lymph nodes, and five distant metastases (DM) coming from the gallbladder (DM036), brain (DM078), liver (DM087), spleen (DM107) and breast (DM116). Bars indicate the number of proteins quantified in each sample. The cell composition of each sample, taking into account tumor cell, stroma, and immune cells was estimated and expressed in percentage of the total sample area. The heatmap was built with the relative abundance levels shown as Z-scores of the six protein elements of the mini-chromosome maintenance complex and four clusters were created to represent the proliferation status of the samples. The abundance of the proliferation marker Ki-67 was plotted for each sample in the proliferation groups. A line indicates the mean value for each group relative to the most proliferative sample group. The colored connection arcs link the samples' origin with their proliferation status.

Gil J. et al. | Malignant melanoma proteogenomics

2.4. Melanoma proliferation relies on repressing the immune system response-related pathways

We sought to gain a deeper understanding of what processes are altered with increased tumor cell proliferation. This was addressed using the proteomic data of the 60 tumor tissue samples and 56 paired plasma samples as well as the Skin Cutaneous Melanoma TCGA PanCancer data with 443 tumor tissue samples (involving 20531 transcripts). TCGA tissue samples were classified into proliferation groups based on the MCM complex levels (in the same manner as the proteomic dataset), whereas the plasma samples were annotated according to the corresponding tissue sample. Sparse partial least squares discriminant analysis (sPLS-DA, ²⁷) of these plasma samples showed there is good discrimination between the high and low proliferation groups, indicating that tumor proliferation status is reflected in the plasma proteome (**Figure 4D**).

Differential expression analysis resulted in 598 proteins (Figure 4A) and 1523 transcripts (Figure 4B) with significant differential expression across the proliferation groups (ANOVA test FDR < 0.001). The overlap between these significant components was rather sparse on the gene level (Figure 4C), however, this list of proteins and genes both suggest an upregulation of cell cycle processes. Also, similar upregulation of proteins that were involved in the organization and localization of cellular components, and an increased biosynthesis of nucleotides. The latter process is particularly important for proliferation because nucleotides cannot be directly taken up from the extracellular space in larger quantities ²⁸. We additionally performed preranked Gene Set Enrichment Analysis (GSEA) to see which MSigDB hallmark gene sets are concordantly up-, or downregulated in highly proliferating tumors. The majority of these processes received similar enrichment scores, in both omics data (Figure 4E), strengthening the idea, that RNA-level data from TCGA is a valuable resource for supplementing our protein-level results. We observed a systematic downregulation of immunerelated processes, which is associated with increased proliferation, possibly due to a lack of immunoediting at a more progressed stage of the disease ²⁹. The relation between immune system modulation and tumorigenesis in melanoma has been studied for the past few years, where today immunotherapies are the most effective treatment options for melanoma patients ³⁰. Our observation provides evidence, supported by the high mutational load, that melanoma development and proliferation rely on evasion of the immune surveillance by downregulating immune response-related pathways.

Plasma proteins with altered abundance profiles across proliferation groups were delineated by selecting the top 100 proteins that drive the discrimination of groups according to the sPLS-DA analysis. These proteins are related to the: immune system, extracellular structure organization, vesicle-mediated transport, platelet degranulation and activation, acute-phase, cell migration, and apoptosis (Figure 4F). It has been shown that the platelets play a central role in the tumor growth and metastasis development in, melanoma, along with additional other cancer diseases. There is evidence postulating that tumor cells interact with platelets, thereby inducing aggregation as well as degranulation ^{31–34}. Regarding the extracellular structure organization, it has been shown that extracellular matrix proteins have a role in the cell transformation process since they are responsible for the interaction between cells and the microenvironment ³⁵. Moreover, inflammatory process and cancer development are inter-connected, positioning acutephase proteins as potential biomarkers in several types of cancer ³⁶. Some members of these plasma proteins are prognostic serum/plasma biomarkers (LDH ³⁷, e.g., Serum amyloid A ^{36,38,39}), with increased expression in patients with short survival (CRP ^{36,40}, as well as ORM1 ⁴¹). Notably, all these proteins were identified as upregulated in the medium-high/high proliferative groups, which indicates a correlation to tumor cell proliferation. The observation that the main plasma proteins that discriminate between groups of tumors based on proliferation are mainly involved in biological pathways and processes related to the response of the immune system, has strong implications on the influence that melanoma exerts on the immune system, outside their physical limits.

Gil J. et al. | Malignant melanoma proteogenomics




Figure 4. Biological processes altered with increased proliferation are similar across tumor proteome, tumor transcriptome, and plasma proteome. A) Volcano plot of the -log10 transformed ANOVA test p-value (FDR-corrected) and the average log₂ FC_{High-Low} of the proteins, and the Gene Ontology Biological Process (GO BP) over-representation analysis of the significant proteins (FDR < 0.001). **B)** Volcano plot of the -log10 transformed ANOVA test p-value (FDR-corrected) and the average log₂ FC_{High-Low} of the proteins, and the Gene Ontology Biological Process (GO BP) over-representation analysis of the significant proteins (FDR < 0.001). **B)** Volcano plot of the -log10 transformed ANOVA test p-value (FDR-corrected) and the log₂ FC_{High-Low} of transcripts, as well as the GO BP over-representation analysis of the significant transcripts (FDR < 0.001). **C)** Overlap between significantly overexpressed proteins and transcripts in higher proliferation groups. **D)** sPLS-DA on melanoma plasma proteome. Ellipses delimit the sample groups created based on the proliferation status of the corresponding tumor samples. **E)** Enrichment scores for hallmark gene sets as provided by pre-ranked GSEA. The analysis provides further evidence that similar processes are up- and downregulated

Gil J. et al. | Malignant melanoma proteogenomics

with increased proliferation in both data sets. F) Biological pathways and processes significantly enriched in the top plasma proteins discriminating between high and low proliferation.

2.5. Study of the melanoma kinome in the context of tumor proliferation

The study of the kinome through proteomics and phosphoproteomics provided further insight into the interplay between tumor proliferation and the repressed immune system. We first explored the kinome data of our sample cohort (including non-tumor and tumor microenvironment samples) comprehensively. We identified members of each major protein kinase class, with a fairly even distribution (Figure 5A). Out of the 522 human kinases present in the KinMap database ⁴², we were able to directly identify 334 kinases, from which 297 and 232 were quantified in our proteomic and phosphoproteomic data respectively. Furthermore, we performed motif analysis using motifeR ⁴³ on the phosphorylated peptides and found 104 enriched motifs. These are predicted to be substrates of 260 kinases, out of which 58 kinases were not experimentally identified in our study. The number of identified and predicted kinases thus reached 75% of all human kinases, which indicates that our data of the melanoma proteome and phosphoproteome can capture the majority of phosphorylation events occurring in melanoma (Figure 5B-C). The GMGC group is an interesting kinase family where many kinases were detected at the protein level, which we also found to be upregulated in highly proliferating tumors. This group entails cyclin-dependent kinases (CDK) as well as mitogen-activated protein kinases (MAPK), both mediators of cell proliferation ^{44,45}.

Turning our focus only to the tumor tissue samples, we were interested in the changes of kinase activities between high and low proliferating tumors. We performed kinase-substrate enrichment analysis using the KSEA App ^{46–49} which allows us to computationally infer the relative kinase activity based on the quantitative phosphoproteomic data. We identified 20 kinases for which at least 5 substrates were quantified in our data, and also showed altered activity (the p-value of the kinase Z-score was less than 0.15) (**Figure 5D**). Many of these kinases are well-

known to be directly or indirectly regulators of cell proliferationrelated processes, as expected. Interestingly, we identified multiple kinases involved in the immune system which has been mentioned in the literature as notable players in immunotherapies. A recent study suggested that CDK1 might contribute to a mechanism that induces immune escape in hepatocellular carcinoma and could be utilized to predict the patient's response to immunotherapy ⁵⁰. Another study on SKOV3 ovarian carcinoma cells proposed that CDK2 (and CDK4) may play an important role in the proliferation-promoting effects of tumor-associated macrophages ⁵¹. mTOR is viewed as a potential oncogene in targeted immunotherapies as studies suggest that the mTOR signaling is vital in the functions of the immune cells ⁵². The GSK3 kinase (ergo its two isoforms, GSK3A and GSK3B) have been proposed to be a good candidate for immunotherapy, as its inhibitors promote an immune response against a wide range of human cancer cells, including melanoma ⁵³. The RAF kinases (ARAF, BRAF, CRAF) are intensively studied due to their role in tumorigenesis regulation, however, it was also found that they are required for the differentiation and function of dendritic cells ⁵⁴. PRKCA was shown to be involved in the proliferation and differentiation of immune cells, although its function shows both pro- and anti-oncogenic properties 55. Moreover, PRKCA phosphorylates TRPC1 and thus regulates the Ca2+ entry in human endothelial cells ⁵⁶. A research study recently suggested that tumors that harbor loss-of-function PRKDC mutations, including melanoma, may benefit from immune therapy ⁵⁷. The inactivation of SGK1 can be associated with anti-oncogenic effects both on tumor cells and on the immune microenvironment and is considered a potential target in non-small cell lung cancer ⁵⁸. In summary, our kinome data suggested the importance of a couple of kinases in melanoma cell proliferation and the regulation of the immune system. To the best of our knowledge, not all kinases were previously connected to melanoma, thus, the role of these kinases at the level of immune-regulation in this particular cancer is yet to be established.






Figure 5. Kinase activities altered with increased proliferation. A) A kinome tree illustrating the wide range of kinases identified and predicted in our multi-omic study of tissue samples (including non-tumor and tumor microenvironment samples). Coloring of the branches was according to the mean log2 FC (higher vs lower proliferation status) of the kinases. The figure was made using Coral ⁵⁹. **B)** Venn diagram indicating the number of

Gil J. et al. | Malignant melanoma proteogenomics

kinases directly identified in our proteomic and phosphoproteomic data, and the overlap between the predicted and identified kinases. **C)** The top 8 enriched motifs in the phosphoproteome. The peptide sequence motif plots were generated using motifeR. **D)** Inference of relative kinase activities between higher and lower proliferating tumors using kinase-substrate enrichment analysis. Here we show only the kinases for which at least 5 substrates were detected in the phosphoproteomic data and showed significantly altered activity (p-value of the Z-score < 0.15). The total amount of detected substrates (phosphopeptides), as well as the protein abundance change for each kinase between high and low proliferation groups (if available) is also noted. Grey colored cells represent a missing value.

2.6. Metabolic reprogramming in melanoma

The metabolic shift from oxidative phosphorylation to glycolytic phenotype has been considered an established common feature for most cancers ^{60,61}. Previously, it was reported that melanoma metastases upregulate glycolysis compared to primary tumors ¹⁰. Our observations confirm that melanoma shows upregulation of the glycolysis, moreover, its upregulation correlates with high proliferation (**Figure 6A-B**). The isoforms M1 and M2 of the pyruvate kinase (PKM) gene are produced by differential splicing. PKM-M1 is the main form in muscle, heart, and brain, and PKM-M2 is found in early fetal tissues as well as in most cancer cells. In melanoma we found PKM-M2 upregulated in all tumor sample groups and the tumor microenvironment, confirming the hypothesis that metabolic reprogramming in melanoma extends to the tumor microenvironment (**Figure 6C**). The upregulation of the hexokinases (HK1-3), and the Phosphoenolpyruvate

carboxykinase (PCK2) support the accumulation of intermediates of glycolysis required for cell proliferation. However, the enzymes involved in the conversion of pyruvate to Acetyl-CoA were upregulated in tumors, which indicates that part of glycolysis intermediates are directed to the TCA cycle. In addition to the glycolysis, the tumors and their microenvironment significantly upregulated the oxidative phosphorylation (OXPHOS) and the mitochondrial translation (Figure 6D). These findings suggest that to support their high proliferation rate, tumors rely on glycolysis and OXPHOS for the production of energy and proliferation-related intermediates. In agreement with these results, we found that most of the protein elements of the hypoxia-inducible factor 1 (HIF-1) signaling pathway were upregulated in tumors (Figure 7A). Consequently, the activation of the HIF-1 signaling pathway provides melanoma with a continuously proliferating activation signal, even under conditions of nutrient deprivation.






Figure 6. Melanoma progression is characterized by alteration of energy production pathways. A) Hierarchical clustering and heatmap of the Pearson correlation values between the relative abundance of proteins reported as part of the glycolysis pathway and the groups of samples based on the sample origin and the proliferation status. Two major protein clusters were identified, those that show a negative correlation (blue rectangle)

Gil J. et al. | Malignant melanoma proteogenomics

and those that show a positive correlation (red rectangle) with the melanoma progression and higher proliferation. **B**) Schematic representation of the glycolysis pathway where the proteins identified and quantified in the study were highlighted. The proteins that are marked with red and blue color show a correlation between their abundance profile and the progression of the disease (red: positive, blue: negative correlation) The protein pyruvate kinase PKM is also highlighted in pink, for which two isoforms were identified and PKM-M2 showed a strong positive correlation with the disease progression while the PKM-M1 isoform showed a weak negative correlation. **C**) Relative abundance of proteins across different sample groups. Grouping was both based on the sample origin (from Non-tumor to Distant metastasis) and based on the proliferation status (from Low to High proliferative). Selected proteins were: hexokinases 1-3 (left panels), phosphoenolpyruvate carboxykinase [GTP], mitochondrial, and isoforms M1 and M2 of the pyruvate kinase PKM (right panels). **D**) Mitochondrial oxidative phosphorylation and translation machinery pathways altered across different sample origins and proliferation groups. Proteins reported to be involved in the Oxidative phosphorylation pathway (upper panel) and those involved in mitochondrial translation (bottom panel) were plotted with their mean relative level in the groups of samples. *, **, *** and **** means significant differences between groups (p<0.05, p<0.01, p<0.001 and p<0.0001 respectively).

Moreover, the calcium signaling pathway which impacts the metabolism and the proliferation of the cell was found dysregulated in melanoma (**Figure 7B**). Proteins involved in controlling the levels of intracellular calcium showed dysregulation. Plasma membrane calcium-transporting ATPases 1, 3, and 4 (ATP2B1, ATP2B3, and ATP2B4), involved in the active release of intracellular calcium through the plasma membrane, were downregulated in the microenvironment. In the case of

ATP2B4, it was also significantly downregulated in tumor groups compared to non-tumors. On the other hand, the main intracellular calcium-binding protein, calmodulin, was upregulated in the microenvironment and all tumor sample groups compared to non-tumors (**Figure 7C**). These findings highlight the dependence of melanoma on intracellular calcium, at the level of preventing the release of calcium not only from tumor cells but also from their microenvironment.

Gil J. et al. | Malignant melanoma proteogenomics




Figure 7. Hypoxia-inducible factor 1 and Calcium signaling pathways are dysregulated during melanoma progression. A) Schematic representation of Hypoxia-inducible factor 1 signaling pathway where proteins identified in the study are highlighted. Color indicates the correlation observed

Gil J. et al. | Malignant melanoma proteogenomics

between the protein levels and the groups of samples (see legend). B) Schematic representation of Calcium signaling pathway where proteins identified in the study are highlighted. Color indicates the correlation observed between the protein levels and the groups of samples (see legend). C) Relative levels of the ATPases 1, 3 and 4 (ATP2B1, ATP2B3 and ATP2B4) and calmodulin in groups of samples based on the origin.

2.7. Lysine acetylation in melanoma

The acetylation workflow allows not only the identification of site-specific lysine acetylation, but also of the stoichiometry impacting the melanoma staging. On average, more than 1100 peptides and 800 proteins were identified carrying acetylation marks in tumor samples, while for non-tumor and microenvironment samples the acetylated peptides and proteins were about 500 and 350 respectively (Figure 8A). The abundance distribution of acetylated proteins highlights the fact that with the current technology and workflow, we can detect acetylation sites and quantify their occupancy in relatively higher abundant proteins compared to the total of identified proteins (Figure 8B). This is a reflection of what has been previously reported, that acetylation in lysine residues is a post-translational-modification that generally shows very low occupancy on their target sites ^{13,62,63}. In all the samples submitted to the analysis the sitespecific occupancy distribution was very similar. At least 50 % of the acetylated peptides identified in all samples, showed a stoichiometry of less than 15% (Figure S5), which is also highlighted after normalization of the data using probit transformation ^{64,65} (Figure 8C).

The melanoma acetylome reported here includes about 3000 proteins, in most of them, only one acetylation site was detected. However, it was found that several proteins have multiple acetylation sites (**Figure 8D**). Particularly, the 100 topmost acetylated proteins were found with at least 7 different acetylated peptides. A functional annotation enrichment analysis of the proteins with at least 7 acetylation sites in melanoma reveals that acetylation regulates pathways involved

in the cytoskeleton, its organization, the actin filaments, and the regulation of cell shape. Besides, as previously reported, a large number of proteins from the translation machinery, the spliceosome, and metabolic enzymes were found to have multiple acetylation target sites ^{66,67} (**Figure 8E**). Among the proteins with more acetylation sites in melanoma, we also found a cluster of biological annotations that includes the protein process and presentation to be significantly enriched. Particularly these pathways are among the most mutated and dysregulated in melanoma. These findings reveal an important role of lysine acetylation in the regulation of critical pathways for melanoma development and progression.

From the proteomic data, we were able to quantify in at least two-thirds of the samples 9 out of the 18 deacetylases reported in the human genome. HDAC1 and 2 from class I, HDAC4 and 7 from class IIa, HDAC6 from class IIb, and four out of the seven sirtuins or class III HDACs (SIRT2, 3, 5, and 6). The role in cancer of several members of these families has been highlighted ^{68–70}. In melanoma, several clinical studies have shown benefit to the patients by targeting HDAC class I, particularly for those with acquired resistance to targeted therapy ⁷¹. The combination of HDAC inhibitors with immunotherapy has shown an enhanced response to the therapy ^{72,73}. Here we show that most of these enzymes, not only are upregulated in melanoma but also their abundance is higher in the more proliferative groups of tumors (Figure 8F). The relative level of the deacetylase enzymes in melanoma together with quantitative analysis on the sitespecific acetylation targets allow a better understanding of how the treatment with HDAC or specific target inhibitors can be implemented in a personalized treatment strategy.






Figure 8. Lysine acetylome in melanoma. A) Identified acetylated peptides and proteins in melanoma-related tissue biopsies, distributed based on sample origin. **B)** Abundance distribution based on the sample origin of all identified proteins and those detected being acetylated. **C)** Frequency distribution of site-specific occupancy of acetylated peptides in each sample. The original values in percentage of the site modified were probit transform before plotting to fit normal distributions. **D)** Distribution of acetylated proteins based on the number of acetylated peptides identified in melanoma-related biopsies. Dashed line delimits the proteins with at least 7 different acetylated peptides in the study (122). **E)** Most targeted proteins with acetylation as a post-translation modification in melanoma are connected to their most relevant enriched functional annotation clusters. The enrichment analysis was performed in DAVID Bioinformatics ⁷⁴. **F)** Hierarchical clustering of the tissue samples based on the relative protein abundance of the nine enzymes with reported deacetylase activity, identified in at least two-thirds of the samples.

2.8. The melanoma progression involves repression of the tumor amino acid metabolism pathway and the evasion of the immune surveillance

Primary tumors, when compared to non-tumors upregulate proliferation-related pathways such as DNA replication,

ribosome biogenesis, spliceosome, and RNA transport. Oppositely, tumors downregulate a set of proteins involved in the communication with the extracellular environment and cell adhesion (**Figure 9C**). The changes in the metabolism of the primary tumors include downregulation of pathways linked to the degradation of amino acids and fatty acids. When compared

Gil J. et al. | Malignant melanoma proteogenomics

to non-tumors, although the tumor microenvironment samples do not show upregulation of proliferation-related pathways as primary tumors do, they show similar alterations in the pathways related to the extracellular matrix communication (**Figure 9A-C**). Interestingly, similar pathways and biological annotations of the proteins were significantly enriched in proteins dysregulated at the level of acetylation in their lysine residues. The glycolysis pathway, which upregulation has correlated with the development of melanoma, was found under-acetylated in both primary tumors and their microenvironment compared to nontumors. Similar results were obtained for ribosomal and translational proteins, suggesting that acetylation on those proteins could primarily have a downregulatory effect on the pathways. Oppositely, several proteins involved in the extracellular matrix and cell-cell adhesion, downregulated in primary tumors showed increased levels of acetylation (**Figure 9D-F**).






Figure 9. Dysregulated proteome and acetylome in primary melanoma and their microenvironment. Biological pathways significantly enriched when comparing the mean protein abundances between the group of samples based on their origin, according to 1D functional enrichment analysis provided by Perseus software ⁷⁵. Data is represented as volcano plots where the annotation enrichment p-value and the score of the differences were plotted. A false discovery rate (FDR) of 0.02 was set as the cut-off for significance. **A)** Comparison between the tumor microenvironment and the non-tumor samples, **B)** between the primary tumor and the tumor microenvironment, and **C)** the primary tumor and the non-tumor. **D-F)** Functional annotation clusters significantly enriched in acetylated proteins that showed significant differences in their site-specific acetylation

Gil J. et al. | Malignant melanoma proteogenomics

occupancy between origin-based groups. D) Comparison between the tumor microenvironment and the non-tumor samples, E) between the primary tumor and the tumor microenvironment, and F) the primary tumor and the non-tumor.

Among the most mutated genes in melanoma identified as hot spot, it was highlighted several members of the antigen presenting MHC class I and class II. A quantitative analysis from the proteomic data reveals that when taken together, the members of the MHC class I on average show lower level in the metastasis groups compare to both non-tumor and primary tumors, although not all the comparisons were statistically significant (Figure 10A (left panel)). Moreover, when analyzing only the tumor samples grouped based their proliferation groups, there is a downregulation of this proteins in relation to the proliferation. The average repression of this proteins, between the high and low proliferative groups, was found to be significant (Figure 10A (right panel)). Similar results were obtained from the analysis on the identified family members of the MHC class II (Figure 10B). These findings provide more insight into how melanoma manages to evade the immune surveillance, by heavily mutating and downregulating the antigen processing and presenting machinery, which ultimately affect the immune system response ⁷⁶.

The progression of melanoma from primary lesions towards metastasis was studied through a biological pathway enrichment analysis on dysregulated proteins between metastases and primary melanomas. Represented pathways were found significantly dysregulated in at least one of the metastasis groups compared to primary tumors (Figure 10C). The metabolic changes in metastatic melanoma continue with the downregulation of the amino acid metabolism, as observed in the comparison between the primary and non-tumor samples. Similarly, pathways linked to the communication with the extracellular environment, including proteins involved in cell-cell adhesion were downregulated in metastases. In this sense, the repression of amino acid metabolic and cell communication pathways is a common feature of melanoma development and progression. Additionally, one of the most relevant characteristics of metastatic melanomas compared to primary tumors is the downregulation of immune system responserelated pathways (Figure 10C). The repression of pathways linked to the immune system is a common feature of melanoma proliferation and progression. Pathways involved in DNA replication and repair, transcription, and translation showed upregulation in the metastasis groups, mostly in cutaneous metastases. Altogether, the aggressiveness of melanoma is supported by a combined upregulation of proliferation-related pathways, rewiring of the metabolism, and repressing the immune system response.

Gil J. et al. | Malignant melanoma proteogenomics




Figure 10. Melanoma progression toward metastasis is driven by changes in the metabolism and downregulation of the immune system-related pathways. Relative levels of the identified family members of the MHC class I (A) and class II (B). Samples were grouped based on their tissue origin (left panels), and based on their proliferation status (right panels). C) Dysregulated biological KEGG pathways between the primary tumors and the different groups of metastases included in the study. The pathways were distributed according to their classification (general and specific). Bar length correspond to the –log10 (q-value), and the gray area correspond to non-significantly enriched. Negative and positive values correspond to down-and upregulated in the metastasis compared to the primary tumor group, respectively.

3. Discussion

In this study, we provided new insights into the progression of melanoma through a comprehensive proteogenomic analysis on primary-, and metastasis tumors, including 77 tissue-, and 56 plasma- samples from 47 melanoma patients and with various

sample origins (non-tumor, tumor microenvironment, primary tumor, local recurrence, cutaneous, lymph node, and distant metastasis). We included deep proteomics and PTM data accompanied by whole exome sequencing to provide an integrated characterization of MM. Several studies have been conducted in large melanoma cohorts using high throughput omic analyses ^{8,9,77} to gain a better understanding of the

Gil J. et al. | Malignant melanoma proteogenomics

molecular mechanism that underlies the development and progression of melanoma. We emphasize the processes that are dysregulated with increased melanoma cell proliferation. Hence, we inferred the proliferation status of each tissue sample based on the relative protein levels of the MCM complex elements. The plasma samples originating from patients with high or low proliferation tumors were also distinguishable at the plasma proteome level. Including the Skin Cutaneous Melanoma TCGA PanCancer data in the analysis, we further validated and supplemented our findings using a larger sample cohort.

Whole exome sequencing of the tumor samples highlighted that mutations occurring in melanoma stem from similar underlying molecular mechanisms in all samples. Hot spot analysis identified 132 genes with frequent somatic mutations, and notably, many members of this list were known to be interactors or regulators of the immune system, such as the MHC class I and II elements. Furthermore, the signaling cascades (MAP kinases and PI2K-AKT) and the calcium homeostasis were the most heavily dysregulated pathways due to the high mutation burden in melanoma. These observations on exome level were reaffirmed on protein level. Firstly, we systematically identified proteins and genes that indicate the suppression of the immune response throughout our analyses, both during the exploratory analysis of the tissue and plasma proteome and the TCGA data, and both during the more targeted analyses. Our findings point to a direct link between the repression of members of the MHC family by mutations or translational downregulation, and progression of melanoma. Moreover, we found this repression in correlation to tumor proliferation. The relation between immune system modulation and tumorigenesis in melanoma has been extensively studied for the past few years, as increased proliferation and lack of immunoediting go hand in hand at a more progressed stage of the disease 78-80. While immunotherapies are the most effective treatments for melanoma patients nowadays, far from all patients respond favorably, and there is therefore still a need for increasing our knowledge of melanoma biology to develop new therapies, strategies to overcome resistance, and increase the number of patients responding to the immunotherapeutic agents ^{29,30}.

The quantitative analysis of two of the most important posttranslational modifications, the phosphorylation and lysine acetylation, deeply complements the proteomics analysis by adding elements of regulation at a level usually ignored by other large-scale analyses. Our analysis of the melanoma kinome highlighted that 75% of all human kinases were detected or predicted based on their phosphorylated targets, which allows to capture the major phosphorylation events. The kinasesubstrate analysis outlined multiple kinases that are activated or deactivated with increased proliferation. Moreover, several of these kinases are considered potential therapeutic targets due to their role in the function of the immune system, such as the GSK3A kinases or the SGK1. Additionally, to the best of our knowledge, this is the first lysine acetylome stoichiometry analysis reported for a large number of melanoma tumor samples. Our observations highlight that the translation machinery and metabolic enzymes are regulated by acetylation and as a general trend lower acetylation degree resulted in upregulation of the pathway. This is particularly interesting because several of the deacetylase enzymes identified in the study were indeed upregulated in melanoma. Our findings support previous reports that HDAC inhibitors treatment in melanoma particularly in combination with immunotherapy enhance the response of the patients ^{72,73,81}.

We found that both glycolysis and OXPHOS are utilized by highly proliferating melanoma cells to produce energy and the proliferation-related intermediates, supported by the observed activation of the HIF-1 signaling pathway, leading to continued proliferation even in the event of nutrient deficit. We further characterized melanoma by the downregulation of proteins involved controlling the levels of intracellular calcium, the repression of amino acid metabolism, and the suppression of cell communication. The observed metabolic reprogramming extended to the tumor microenvironment, but was not discovered in non-tumor samples.

We acknowledge the limitations of our study. An experimental design involving samples from 7 different tissue origins is ultimately more prone to bias due to the low sample sizes within each sub-cohort. Nonetheless, the integration of genetic level information and PTM data next to proteomics represents a rich resource to investigate melanoma biology, and main observations from one type of omic data were supplemented on another molecular layer, thus confirming the validity of our results. We envision that the hypotheses underlined in this manuscript will contribute to a better understanding of melanoma and will aid the development of new therapies.

4. Experimental section

4.1. Sample processing and peptide/protein identification

A protein extraction buffer containing SDS 2%, DTT 50 mM, Tris 100 mM, pH 8.6, was added to the sliced tissues or cell pellet, rest for one minute, and sonicated using a Bioruptor plus (40 cycles, 15 s On, 15 s Off, at 4 °C). Samples were incubated at 95 °C for 5 min. Proteins were alkylated by adding IAA to a final concentration of 100 mM for 20 min in the dark at room temperature (RT). The proteins were precipitated overnight by adding 9 volumes of cold ethanol. Proteins were dissolved in TEAB buffer containing SDS 1%, SDC 0.5%, and submitted to a chemical acetylation reaction of all free amino groups. The reaction was performed with N-acetoxy-succinimide-d3 (NASd3). O-acetylation was reverted by treating the samples with 5% hydroxylamine. Proteins were precipitated as described above to remove the excess reagents and dissolved in AmBiC containing SDC 0.5%. Proteins were digested with trypsin (1:50, enzyme:protein) at 37 °C, overnight. The SDC was removed from

Gil J. et al. | Malignant melanoma proteogenomics

the peptide solution by adding ethyl-acetate and TFA ¹³. After discarding the organic phase, the mixtures of peptides were quantified and kept at -80 °C until MS analysis.

For phosphopeptide enrichment, 80 mg of peptides was submitted to an automated workflow, performed on an AssayMAP Bravo system (Agilent Technologies). The procedure was performed as previously described ¹¹. Phosphopeptides were dried and kept at -80 °C until MS analysis.

Peptide spectral library: Pools of peptides including all the tumor samples were spiked with iRT and analyzed in a high-resolution LC-MS system (Dionex Ultimate 3000 RSLCnano UPLC coupled to a Q-Exactive HF-X mass spectrometer (Thermo Fischer Scientific)). Peptides were desalted on a trap column Acclaim PepMap100 C18 (3 μ m, 100 Å, 75 μ m i.d. × 2 cm, nanoViper) and then connected in line with an analytical column EASY-spray RSLC C18 (2 μ m, 100 Å, 75 μ m i.d. × 50 cm). The temperature of the trap column and analytical column was set at 35 °C and 60 °C respectively, and the flow rate was 300 nL/min. A non-linear gradient of 137 min was used for peptide elution. Data were acquired applying a DDA method covering a mass range of 385-1460 m/z. The parameters for MS1 included a resolution of 120,000 (@ 200 m/z), the target AGC value of $3 \cdot 10^6$, and the maximum injection time was set at 100 ms. For MS2, the resolution was 15,000, the AGC value $1 \cdot 10^5$, the injection time 50 ms, the threshold for ion selection $8 \cdot 10^3$, and the normalized collision energy (NCE) 28. The isolation window was 1.2 Th.

DIA analysis: samples were analyzed in duplicates using the same LC-MS system and with the same chromatographic conditions as described above. Data were acquired using a DIA method intended for peptide quantification using MS1 scans. The DIA method contains 54 variable width MS2 windows, based on the empirical distribution of peptides, and 3 full scan MS1. A full MS1 scan was placed every 18 MS2 scans. The parameters for MS1 were: resolution 120,000 (@200 m/z), AGC target 3E+06, injection time 50 ms, range 385-1460 Th. For the MS2 were: resolution 30,000, AGC target 1.10⁶, injection time 50 ms, NCE 28.

Protein and peptide identification and quantification were performed with the Spectronaut software (Biognosys, AG). DDA raw files were searched against a human protein database downloaded from UniProt in 2018, to create a spectral library. The search engine used was pulsar, which is integrated into the Spectronaut platform. The parameters included Arg-C as the cleavage enzyme, 2 missed cleavages were allowed, lysine acetylation (d3) and carbamidomethyl-cysteine were set as fix modifications, methionine oxidation and protein N-terminal acetylation (d3) and (d0) were set as variable modifications. For the postmortem cohort, the selected enzyme was trypsin, two missed cleavages were allowed, carbamidomethyl-cysteine was fixed, and methionine oxidation and protein N-terminal acetylation were set as a variable. The identifications were controlled by an FDR of 1% at the PSM, peptide, and protein levels.

For identification and quantification of lysine acetylation, raw files were analyzed by two different software Pview ⁸² and (Thermo scientific). Proteome discoverer Acetylation stoichiometry was only considered for those peptides commonly identified by the two search engines. The parameters included Arg-C as the cleavage enzyme, carbamidomethyl cysteine as fix modification, methionine oxidation, and lysine acetylation (d0 and d3) were set as variable modifications. The number of identifications was controlled by FDR of 1% at peptide and protein level. The parameters for the stoichiometry calculation were as previously reported ¹³. For comparison of the acetylation occupancy between groups, a probit transformation of the data was applied.

4.2. Proteomic, phosphoproteomic, and transcriptomic data processing, statistics, and bioinformatics

The data processing and statistics were performed in R (vs. 4.0) unless specified otherwise. The Skin Cutaneous Melanoma TCGA PanCancer data ^{9,83,84}) was downloaded from the cBioPortal website ^{85,86}.

A similar data pre-processing workflow was applied on protein and phosphopeptide intensities as well as on the transcriptome data. For the RNA expressions, counts equal to 0 were treated as NA values. Intensities/counts were log₂ transformed, followed by global median centering for normalization, and sample replicates averaging in case of the proteomic data. The correlation in abundance between proteins from the MCM protein complex was used as a criterion to evaluate the normalization performance. Differential expression analysis was performed using Analysis of Variance (ANOVA test), followed by ANOVA pvalue adjustment with the Benjamini-Hochberg method and an additional Tukey-Kramer post hoc test for each ANOVA analysis. No prior filter for valid values was applied on either data set, however, only those groups were compared where the protein/phosphopeptide/gene had valid values in at least 70% of the groups' samples. Comparison between proteomic and transcriptomic signatures related to proliferation status was done using Gene Set Enrichment Analysis (GSEA) on the 50 hallmark gene sets that were downloaded from http://www.gsea-msigdb.org/gsea/msigdb/index.jsp. The ordered list of mean log2 FC values across the proliferation groups was used as the input and no p-value threshold was set. The hallmark gene sets were further categorized according to Liberzon et al.⁸⁷. Gene Ontology over-representation test on the biological processes and Gene Set Enrichment Analysis was performed using the R package "clusterProfiler" (vs. 3.18.1).

Kinome analysis: The list of human kinases was downloaded from <u>http://www.kinhub.org/kinases.html</u> (on 10 March 2021).

Gil J. et al. | Malignant melanoma proteogenomics

Sequence pre-alignment and motif analyses were done using the motifeR web server (https://www.omicsolution.org/wukong/motifeR/). In this analysis, we included only the phosphopeptides that were identified in at least 30% of the samples and where the phosphorylation site was confidently identified (8994 sequences). Sequence data were aligned to have 15-amino-acid long sequences where the central residue is the phosphorylated S/T amino acid. For the motif analysis, the following settings were applied: each motif had to appear at least 20 times in the data set, and the p-value threshold for the binomial probability was set to 1e-06 for the selection of significant residues in the motif. The default human database was used as a background and classical multiple sites analysis was chosen. Motif enrichment analysis was done both on peptides with one and with multiple modification sites. Kinases were predicted based on all the enriched motifs and the minimum NetworKin score was set to 3.

Kinase-substrate enrichment analysis was performed using the KSEAapp R package. Both curated annotations from PhosphoSitePlus and kinase-substrate predictions from NetworKIN were considered (Kinase-Substrate dataset downloaded from the KSEAapp Github page https://github.com/casecpb/KSEA), and the minimum NetworKIN score was set to 5.

4.3. WES analysis

WES data analysis: The WES sequencing data of the 60 samples were mapped against GRCh38 and analyzed according to standard workflows as described by GATK (Broad Institute). Additional filtering was applied to remove variants with coverage of less than 3 reads. Next, the exome panel enrichment regions Twist from Bioscience (downloaded from https://www.twistbioscience.com/sites/default/files/resources /2019-06/Twist Exome Target hg38.bed) were used to filter out all identified variants outside of these WES targeted regions. The non GCTA nonTCGA gnomAD subset was used as "population background" information to distinguish between variants annotated in this database referred to as germline and those missing (referred to as somatic variants). Summary statistics about the variants in each of these 2 categories were created using the "bcftools stats" utility.

Hot spot analysis: The somatic and germline variant counts were grouped and summed by the gene they overlap with. Chi-square tests were performed to determine genes within individual samples for which the number of somatic variants was different than expected based on the sample's ratio of these counts across all genes. Similarly, the variant counts per gene were grouped and summed on a pathway level. Bonferroni correction was applied on the obtained p-values. Genes with significant enrichment were selected by using the significance level 0.05 and requiring the presence of significant enrichment in $\frac{1}{3}$ of the data (20 out of 60 samples). Data visualization and final statistics were made with a custom R script.

5. Acknowledgments

This study was kindly supported by the Berta Kamprad Foundation, Thermo Fischer Scientific as our strategic partner, The Swedish Pharmaceutical Society and Agilent Technologies. This work was done under the auspices of a Memorandum of Understanding between the European Cancer Moonshot Center in Lund and the U.S. National Cancer Institute's International Cancer Proteogenome Consortium (ICPC)

6. References

1. IARC. Latest Global Cancer Data, 2018. World Heal. Organ. (2018).

2. Leonardi, G. C. *et al.* Cutaneous melanoma: From pathogenesis to therapy (Review). *International Journal of Oncology* (2018) doi:10.3892/ijo.2018.4287.

3. Alexandrov, L. B. *et al.* Signatures of mutational processes in human cancer. *Nature* (2013) doi:10.1038/nature12477.

4. Gara, S. K. *et al.* Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. *Nat. Commun.* **9**, 4172 (2018).

5. Szász, A. M., Győrffy, B. & Marko-Varga, G. Cancer heterogeneity determined by functional proteomics. *Semin. Cell Dev. Biol.* **64**, 132–142 (2017).

6. Betancourt, L. H. *et al.* The hidden story of heterogeneous B-raf V600E mutation quantitative protein expression in metastatic melanoma— association with clinical outcome and tumor phenotypes. *Cancers (Basel).* **11**, 1981 (2019).

7. Dimitriou, F. *et al.* The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. *Current Oncology Reports* (2018) doi:10.1007/s11912-018-0732-8.

8. Harel, M. *et al.* Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence. *Cell* (2019) doi:10.1016/j.cell.2019.08.012.

9. Akbani, R. *et al.* Genomic Classification of Cutaneous Melanoma. *Cell* (2015) doi:10.1016/j.cell.2015.05.044.

10. Gil, J. *et al*. Clinical protein science in translational medicine targeting malignant melanoma. *Cell Biol. Toxicol.* **35**, 293–332 (2019).

11. Murillo, J. R. *et al.* Automated phosphopeptide enrichment from minute quantities of frozen malignant melanoma tissue. *PLoS One* (2018) doi:10.1371/journal.pone.0208562.

12. Adhikari, S. *et al.* A high-stringency blueprint of the human proteome. *Nature Communications* (2020) doi:10.1038/s41467-020-19045-9.

13. Gil, J. *et al*. Lysine acetylation stoichiometry and proteomics analyses reveal pathways regulated by sirtuin 1 in human cells. *J. Biol. Chem.* **292**, 18129–18144 (2017).

Gil J. et al. | Malignant melanoma proteogenomics

14. Das, M., Singh, S., Pradhan, S. & Narayan, G. MCM Paradox: Abundance of Eukaryotic Replicative Helicases and Genomic Integrity. *Mol. Biol. Int.* **2014**, 574850 (2014).

15. You, Z., Komamura, Y. & Ishimi, Y. Biochemical Analysis of the Intrinsic Mcm4-Mcm6-Mcm7 DNA Helicase Activity. *Mol. Cell. Biol.* (1999) doi:10.1128/mcb.19.12.8003.

16. Lee, J. K. & Hurwitz, J. Processive DNA helicase activity of the minichromosome maintenance proteins 4, 6, and 7 complex requires forked DNA structures. *Proc. Natl. Acad. Sci. U. S. A.* (2001) doi:10.1073/pnas.98.1.54.

17. Miller, T. C. R., Locke, J., Greiwe, J. F., Diffley, J. F. X. & Costa, A. Mechanism of head-to-head MCM double-hexamer formation revealed by cryo-EM. *Nature* (2019) doi:10.1038/s41586-019-1768-0.

18. Cao, T. *et al.* Identification of the DNA Replication Regulator MCM Complex Expression and Prognostic Significance in Hepatic Carcinoma. *Biomed Res. Int.* (2020) doi:10.1155/2020/3574261.

19. Issac, M. S. M., Yousef, E., Tahir, M. R. & Gaboury, L. A. MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. *Neoplasia (United States)* (2019) doi:10.1016/j.neo.2019.07.011.

20. Valverde, L. D. F. *et al.* MCM3: A Novel Proliferation Marker in Oral Squamous Cell Carcinoma. *Appl. Immunohistochem. Mol. Morphol.* (2018) doi:10.1097/PAI.00000000000397.

21. Stojkovic-Filipovic, J., Brasanac, D., Bosic, M. & Lekic, B. Minichromosome maintenance protein expression in squamous cell carcinoma. *Melanoma Res.* (2016).

22. Aporowicz, M. *et al.* Minichromosome maintenance proteins MCM-3, MCM-5, MCM-7, and Ki-67 as proliferative markers in adrenocortical tumors. *Anticancer Res.* (2019) doi:10.21873/anticanres.13224.

23. Wojnar, A. *et al.* Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. *Folia Histochem. Cytobiol.* (2010) doi:10.2478/v10042-010-0069-0.

24. Giaginis, C. *et al.* MCM-2 and MCM-5 expression in gastric adenocarcinoma: Clinical significance and comparison with Ki-67 proliferative marker. *Dig. Dis. Sci.* (2011) doi:10.1007/s10620-010-1348-5.

25. Giaginis, C. *et al.* Clinical significance of MCM-2 and MCM-5 expression in colon cancer: Association with clinicopathological parameters and tumor proliferative capacity. *Dig. Dis. Sci.* (2009) doi:10.1007/s10620-008-0305-z.

26. Güzel, C. *et al.* Proteomic alterations in early stage cervical cancer. *Oncotarget* (2018) doi:10.18632/oncotarget.24773.

27. Chung, D. & Keles, S. Sparse partial least squares classification for high dimensional data. *Stat. Appl. Genet. Mol. Biol.* **9**, 17 (2010).

28. Zhu, J. & Thompson, C. B. Metabolic regulation of cell growth and proliferation. *Nature Reviews Molecular Cell Biology* (2019) doi:10.1038/s41580-019-0123-5.

29. Passarelli, A., Mannavola, F., Stucci, L. S., Tucci, M. & Silvestris, F. Immune system and melanoma biology: A balance between immunosurveillance and immune escape. *Oncotarget* **8**, 106132–106142 (2017).

30. Karachaliou, N. *et al.* Melanoma: Oncogenic drivers and the immune system. *Ann. Transl. Med.* **3**, 1–22 (2015).

 Leblanc, R. & Peyruchaud, O. Metastasis: New functional implications of platelets and megakaryocytes. *Blood* **128**, 24–31 (2016).
 Schlesinger, M. Role of platelets and platelet receptors in cancer metastasis 06 Biological Sciences 0601 Biochemistry and Cell Biology. *J. Hematol. Oncol.* **11**, 1–15 (2018).

33. Becker, K. A. *et al.* Melanoma cell metastasis via P-selectin-mediated activation of acid sphingomyelinase in platelets. *Clin. Exp. Metastasis* **34**, 25–35 (2017).

34. Boukerche, H. *et al.* Platelet-melanoma cell interaction is mediated by the glycoprotein IIb- IIIa complex. *Blood* **74**, 658–663 (1989).

35. Botti, G. *et al.* Microenvironment and tumor progression of melanoma: New therapeutic prospectives. *J. Immunotoxicol.* **10**, 235–252 (2013).

36. Shannon, W., H., L., J., R. & A., J. Acute Phase Proteins as Cancer Biomarkers. *Acute Phase Proteins as Early Non-Specific Biomarkers Hum. Vet. Dis.* (2011) doi:10.5772/25181.

37. Karagiannis, P., Fittall, M. & Karagiannis, S. N. Evaluating biomarkers in melanoma. *Front. Oncol.* **4**, 1–11 (2015).

38. Findeisen, P. *et al.* Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. *J. Clin. Oncol.* **27**, 2199–2208 (2009).

39. Malle, E., Sodin-Semrl, S. & Kovacevic, A. Serum amyloid A: An acutephase protein involved in tumour pathogenesis. *Cell. Mol. Life Sci.* **66**, 9– 26 (2009).

40. Fang, S. *et al.* C-reactive protein as a marker of melanoma progression. *J. Clin. Oncol.* **33**, 1389–1396 (2015).

41. Betancourt, L. H. *et al.* Improved survival prognostication of nodepositive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. *Sci. Rep.* (2019) doi:10.1038/s41598-019-41625-z.

42. Eid, S., Turk, S., Volkamer, A., Rippmann, F. & Fulle, S. Kinmap: A web-based tool for interactive navigation through human kinome data. *BMC Bioinformatics* (2017) doi:10.1186/s12859-016-1433-7.

43. Wang, S. *et al.* motifeR: An Integrated Web Software for Identification and Visualization of Protein Posttranslational Modification Motifs. *Proteomics* (2019) doi:10.1002/pmic.201900245.

44. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. *Nature Reviews Cancer* (2009) doi:10.1038/nrc2602.

45. Braicu, C. *et al.* A comprehensive review on MAPK: A promising therapeutic target in cancer. *Cancers* (2019) doi:10.3390/cancers11101618.

46. Wiredja, D. D., Koyutürk, M. & Chance, M. R. The KSEA App: a webbased tool for kinase activity inference from quantitative phosphoproteomics. *Bioinformatics* (2017) doi:10.1093/bioinformatics/btx415.

47. Casado, P. *et al.* Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. *Science Signaling* (2013) doi:10.1126/scisignal.2003573. 48. Hornbeck, P. V. *et al.* PhosphoSitePlus, 2014: Mutations, PTMs and

recalibrations. *Nucleic Acids Res.* (2015) doi:10.1093/nar/gku1267. 49. Horn, H. *et al.* KinomeXplorer: An integrated platform for kinome

biology studies. *Nature Methods* (2014) doi:10.1038/nmeth.2968. 50. Zou, Y. *et al.* CDK1, CCNB1, and CCNB2 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. *Med. Sci. Monit.* (2020) doi:10.12659/MSM.925289.

51. Yang, Y. *et al.* CDK2 and CDK4 play important roles in promoting the proliferation of SKOV3 ovarian carcinoma cells induced by tumorassociated macrophages. *Oncol. Rep.* (2014) doi:10.3892/or.2014.3127. 52. Jin, J. & Zhao, Q. Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. *Theranostics* (2020) doi:10.7150/thno.45219.

53. Augello, G. *et al.* The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. *Cells* (2020) doi:10.3390/cells9061427.

54. Riegel, K. *et al.* RAF kinases are stabilized and required for dendritic cell differentiation and function. *Cell Death Differ.* (2020) doi:10.1038/s41418-019-0416-4.

55. Black, A. R. & Black, J. D. The complexities of PKCα signaling in cancer. *Adv. Biol. Regul.* (2021) doi:10.1016/j.jbior.2020.100769.

Gil J. et al. | Malignant melanoma proteogenomics

56. Ahmmed, G. U. *et al.* Protein kinase Cα phosphorylates the TRPC1 channel and regulates store-operated Ca2+ entry in endothelial cells. *J. Biol. Chem.* (2004) doi:10.1074/jbc.M313975200.

57. Tan, K. T. *et al.* PRKDC: New biomarker and drug target for checkpoint blockade immunotherapy. *J. Immunother. Cancer* (2020) doi:10.1136/jitc-2019-000485.

58. Guerriero, I., Monaco, G., Coppola, V. & Orlacchio, A. Serum and glucocorticoid-inducible kinase 1 (Sgk1) in nsclc therapy. *Pharmaceuticals* (2020) doi:10.3390/ph13110413.

59. Metz, K. S. *et al.* Coral: Clear and Customizable Visualization of Human Kinome Data. *Cell Syst.* (2018) doi:10.1016/j.cels.2018.07.001.

60. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. *Cell* (2011) doi:10.1016/j.cell.2011.02.013.

61. Danhier, P. *et al.* Cancer metabolism in space and time: Beyond the Warburg effect. *Biochim. Biophys. Acta - Bioenerg.* (2017) doi:10.1016/j.bbabio.2017.02.001.

62. Narita, T., Weinert, B. T. & Choudhary, C. Functions and mechanisms of non-histone protein acetylation. *Nature Reviews Molecular Cell Biology* (2019) doi:10.1038/s41580-018-0081-3.

63. Hansen, B. K. *et al.* Analysis of human acetylation stoichiometry defines mechanistic constraints on protein regulation. *Nat. Commun.* (2019) doi:10.1038/s41467-019-09024-0.

64. Singh, N. K. *et al.* In vitro assessment of the acaricidal activity of Piper longum, Piper nigrum, and Zingiber officinale extracts against Hyalomma anatolicum ticks. *Exp. Appl. Acarol.* (2017) doi:10.1007/s10493-017-0113-2.

65. Alamir, A. E., Nenaah, G. E. & Hafiz, M. A. Mathematical probit and logistic mortality models of the Khapra beetle fumigated with plant essential oils. *Math. Biosci. Eng.* (2015) doi:10.3934/mbe.2015.12.687.

66. Choudhary, C. *et al.* Lysine acetylation targets protein complexes and co-regulated major cellular functions. *Science (80-.).* **325**, 834–840 (2009).

67. Norris, K. L., Lee, J. Y. & Yao, T. P. Acetylation Goes Global: The Emergence of Acetylation Biology. *Science Signaling* (2009) doi:10.1126/scisignal.297pe76.

68. Gil, J., Ramírez-Torres, A. & Encarnación-Guevara, S. Lysine acetylation and cancer: A proteomics perspective. *Journal of Proteomics* (2017) doi:10.1016/j.jprot.2016.10.003.

69. Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R. & Marins, M. Roles of histone deacetylases and inhibitors in anticancer therapy. *Cancers* (2020) doi:10.3390/cancers12061664.

70. Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. *Nature Reviews Genetics* (2009) doi:10.1038/nrg2485.

71. Wang, L. *et al.* An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential. *Cell* (2018) doi:10.1016/j.cell.2018.04.012.

72. Booth, L., Roberts, J. L., Poklepovic, A., Kirkwood, J. & Dent, P. HDAC inhibitors enhance the immunotherapy response of melanoma cells. *Oncotarget* (2017) doi:10.18632/oncotarget.17950.

73. Woods, D. M. *et al.* HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. *Cancer Immunol. Res.* (2015) doi:10.1158/2326-6066.CIR-15-0077-T.

74. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* (2009) doi:10.1093/nar/gkn923.

75. Cox, J. & Mann, M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. *BMC Bioinformatics* (2012) doi:10.1186/1471-2105-13-S16-S12.

76. Yoshihama, S. *et al.* NLRC5/MHC class I transactivator is a target for immune evasion in cancer. *Proc. Natl. Acad. Sci. U. S. A.* (2016) doi:10.1073/pnas.1602069113.

77. Hugo, W. *et al.* Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell* (2016) doi:10.1016/j.cell.2016.02.065.

78. Lee, J. H. *et al.* Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. *Nat. Commun.* (2020) doi:10.1038/s41467-020-15726-7.

79. Ghorani, E. *et al.* Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. *Ann. Oncol.* (2018) doi:10.1093/annonc/mdx687.

80. Newell, F. *et al.* Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. *Nat. Commun.* (2019) doi:10.1038/s41467-019-11107-x.

81. Banik, D., Moufarrij, S. & Villagra, A. Immunoepigenetics combination therapies: An overview of the role of HDACs in cancer immunotherapy. *International Journal of Molecular Sciences* (2019) doi:10.3390/ijms20092241.

82. Baeza, J. *et al.* Stoichiometry of site-specific lysine acetylation in an entire proteome. *J. Biol. Chem.* (2014) doi:10.1074/jbc.M114.581843.

83. Hoadley, K. A. *et al.* Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell* (2018) doi:10.1016/j.cell.2018.03.022.

84. Ellrott, K. *et al.* Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Syst.* (2018) doi:10.1016/j.cels.2018.03.002.

85. Cerami, E. *et al.* The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* (2012) doi:10.1158/2159-8290.CD-12-0095.

86. Gao, J. *et al.* Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* (2013) doi:10.1126/scisignal.2004088.

87. Liberzon, A. *et al.* The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Syst.* (2015) doi:10.1016/j.cels.2015.12.004.

Gil J. et al. | Malignant melanoma proteogenomics

7. Supplemental figures




Figure S1. The ratio of various base-pair changes in somatic (A) and germline (B) SNPs compared to population reference (gnomAD_only excluding mutations identified in all tumor samples). The pattern is highly reproducible for both cases with difference between somatic and germline SNPs (A and B).

Gil J. et al. | Malignant melanoma proteogenomics




Figure S2. Distribution of sequence length shortening or extension of indels with somatic (A) and germline (B) origin. Somatic indels tend to extend, while germline indels generally shorten exons and protein variants. Y axis show the range of ± 15 base pair lengths.

Gil J. et al. | Malignant melanoma proteogenomics




Figure S3. Sequence coverage of somatic (A) and germline (B) mutations below 500 reads. log2 ratio of several variants with more than 500 reads and less than 500 reads is somatic and germline mutations (C) in WES data of 60 tumor samples indicating the lower sequence coverage of somatic mutations compared to the germline.

Gil J. et al. | Malignant melanoma proteogenomics




Figure S4. Manhattan plots showing the enrichment of somatic mutations compared to germline in 6 tumor samples shown as examples. Low p-values (I.e., a high $-\log_{10}(p-value)$) indicate a high mutation load of genes at a given chromosomal location (x-axis), indicating a hot spot. Genes found to be significant in at least $\frac{1}{3}$ of the 60 samples were selected as a hotspot in this study and are listed in Table S3. All sample shows a peak in chromosome 6 corresponding to the HLA region.




Figure S5. Distribution of the lysine acetylation stoichiometry in the percentage of occupancy of the target site, in all the solid biopsies enrolled in the study. The dashed line indicates a site-specific acetylation occupancy of less than 15%.

Gil J. et al. | Malignant melanoma proteogenomics

8. Supplementary Tables

Patient Code	Age diagnosis	Gender	Pathological stage	Primary Tumor Type	Braf Mutation Status	Sample	Origin	Proliferation status	Tumor cell (%)	Immune cells (%)	Metastasis treatment
P002	60	Female	PT4B	ALM	V600K	CM002	Cutaneous metastasis	Medium-High	56.72	0.67	YES
P003	75	Female	PT3B	SSM	WT	LR003	Local recurrence	Low	16.95	0.65	NO
P003	75	Female	PT3B	SSM	WT	LR024	Local recurrence	High	13.49	0.76	NO
P004	64	Male	PT3A	NM	V600E	LR075	Local recurrence	High	58.83	0	YES
P004	64	Male	PT3A	NM	V600E	CM004	Cutaneous metastasis	Medium-High	43.02	0.01	YES
P005	81	Female	N/A	N/A	N/A	TM005	Tumor microenvironment	Low	1	0.01	N/A
P005	81	Female	PT3A	SSM	WT	LR005	Cutaneous metastasis	Low	12.6	3.6	NO
P007	74	Female	N/A	N/A	N/A	TM071	Tumor microenvironment	Low	2	53.85	N/A
P007	74	Female	PT4A	UNCLASS	V600K	PT007	Primary tumor	Low	24.57	0.001	N/A
P007	74	Female	PT4A	UNCLASS	V600K	LN071	Lymph node metastasis	Medium-Low	N/A	N/A	NO
P008	67	Female	PT3A	NM	WT	LR008	Local recurrence	Medium-High	26.37	1.34	YES
P008	67	Female	PT3A	NM	WT	CM153	Cutaneous metastasis	Medium-Low	48.01	6.37	YES
P014	67	Male	N/A	N/A	V600E	CM014	Cutaneous metastasis	High	86.50	0.03	NO
P027	69	Male	PT4B	ALM	WT	PT027	Primary tumor	Low	24.19	0.02	N/A
P028	25	Male	PT4B	NM	V600E	PT028	Primary tumor	Medium-High	29.69	0.05	N/A
P028	25	Male	PT4B	NM	V600E	LN090	Lymph node metastasis	Medium-Low	20.52	56.08	NO
P029	83	Female	N/A	N/A	N/A	TM029	Tumor microenvironment	Low	0	0.10	N/A
P029	83	Female	PT1A	SSM	V600E	PT029	Primary tumor	Medium-Low	26	13.4	N/A
P033	71	Male	PT2B	N/A	V600K	LN033	Lymph node metastasis	Low	13.25	20.38	NO
P034	40	Female	PT4B	NM	WT	CM034	Cutaneous metastasis	High	67.49	0.10	NO
P036	59	Male	N/A	SSM	WT	DM036	gallbladder metastasis	Medium-High	30.59	0.80	YES
P037	63	Female	N/A	NM	V600E	LN037	Lymph node metastasis	High	17.36	16.14	NO
P039	84	Male	N/A	N/A	N/A	NT039	Non-tumor	Low	0	0	N/A
P039	84	Male	PT3A	ALM	WT	PT039	Primary tumor	Low	48.53	0.436871032	N/A
P041	81	Male	N/A	N/A	N/A	NT046	Non-tumor	Low	0	0	N/A
P041	81	Male	N/A	N/A	N/A	TM046	Tumor microenvironment	Low	2	0	N/A
P041	81	Male	PT3A	UNCLASS	V600E	PT041	Primary tumor	High	44.24	0.41	N/A
P041	81	Male	PT2A	SSM	V600E	PT046	Primary tumor	Medium-Low	12.41	0.04	N/A
P044	80	Male	N/A	N/A	N/A	NT044	Non-tumor	Low	0	0	N/A
P044	80	Male	N/A	SSM	V600K	PT044	Primary tumor	Medium-Low	39.57	0.51	N/A
P048	68	Female	N/A	N/A	N/A	NT048	Non-tumor	Low	0	0	N/A
P048	68	Female	PT4B	SSM	V600E	PT048	Primary tumor	Medium-High	68.07	0.011	N/A
P050	73	Male	PT4B	UNCLASS	WT	PT050	Primary tumor	High	40.57	0	N/A
P050	73	Male	PT4B	UNCLASS	WT	LN079	Lymph node metastasis	High	19.17	36.59	NO
P054	70	Female	N/A	N/A	N/A	NT054	Non-tumor	Low	0	0	N/A
P054	70	Female	N/A	N/A	N/A	TM054	Tumor microenvironment	Low	2	0.03	N/A
P054	70	Female	PT3B	SSM	V600E	PT054	Primary tumor	Medium-Low	32.2	14.4	N/A
P056	67	Female	N/A	N/A	N/A	NT056	Non-tumor	Low	0	0	N/A
P056	67	Female	N/A	N/A	N/A	TM083	Tumor microenvironment	Low	N/A	N/A	N/A
P056	67	Female	PT3B	UNCLASS	V600E	PT056	Primary tumor	High	26.03	4.80	N/A
P056	67	Female	PT3B	UNCLASS	V600E	LN083	Lymph node metastasis	Low	1.67	6	NO
P057	66	Female	PT3B	UNCLASS	V600K	LN057	Lymph node metastasis	Medium-High	27.67	4.87	YES
P059	39	Female	N/A	N/A	WT	LN059	Lymph node metastasis	Medium-High	18.90	1.52	NO
P060	89	Female	N/A	N/A	N/A	NT060	Non-tumor	Low	0	0	N/A
P060	89	Female	N/A	NM	WT	LR060	Local recurrence	Medium-Low	31.65	2.40	NO
P062	69	Male	PT4B	NM	V600E	LN062	Lymph node metastasis	Medium-High	52.17	0.96	NO
P063	75	Male	PT2B	SSM	WT	LR063	Local recurrence	Medium-High	38.10	0	NO
P066	71	Male	N/A	N/A	N/A	NT066	Non-tumor	Low	0	0	N/A
P066	71	Male	PT3A	UNCLASS	V600E	CM066	Cutaneous metastasis	Medium-High	49.01	0.21	YES
P068	75	Female	N/A	N/A	N/A	NT068	Non-tumor	Low	0	0	N/A
P068	75	Female	PT4B	NM	V600E	PT068	Primary tumor	Medium-High	32.02	0.32	N/A
P069	53	Female	PT2A	N/A	V600E	LN069	Lymph node metastasis	Medium-High	51.69	0.13	NO
P073	58	Male	N/A	N/A	WT	LN073	Lymph node metastasis	High	83.72	0.004	NO
P074	80	Male	N/A	ALM	N/A	LN074	Lymph node metastasis	Medium-High	31.43	0.06	YES
P076	64	Male	N/A	N/A	N/A	LN076	Lymph node metastasis	Medium-Low	47.19	17.62	NO
P078	43	Male	N/A	SSM	WT	DM078	Brain metastasis	Low	23.15	0	YES
P080	39	Male	PT3B	ALM	V600E	LN080	Lymph node metastasis	Low	20.33		
P081	69	Male	N/A	UNCLASS	V600E	LN081	Lymph node metastasis	Medium-Low	36.99		
P082	48	Male	PT4A	NM	WT	PT082	Primary tumor	Medium-High	46.94		
P082	48	Male	PT4A	NM	WT	LN092	Lymph node metastasis	Medium-High	75.22		
P087	23	Male	N/A	N/A	V600E	LN087	Lymph node metastasis	Low	47.69		YES
P087	23	Male	N/A	N/A	V600E	DM087	Liver metastasis	Medium-High	65.37		YES
P089	44	Female	PT4B	ALM	WT	PT089	Primary tumor	Low	41.94		N/A
P089	44	Female	PT4B	ALM	WT	LN093	Lymph node metastasis	Medium-High	41.54		
P091	75	Male	PT4B	NM	V600E	LN091	Lymph node metastasis	High	20.94		
P096	66	Male	N/A	NM	V600L	CM096	Cutaneous metastasis	Medium-High	30.62		
P098	75	Male	N/A	N/A	N/A	LN098	Lymph node metastasis	Medium-High Medium-High	35.09		
P100	67	Male	N/A	NM	V600E	LN098 LN100	Lymph node metastasis	Medium-Low	49.42		
P100 P107	75	Male	PT3A	UNCLASS	V600E	LN100 LN185			35.59		
	/ 2	WIDE	F I SA	UNCLASS	VUUUK	LIN100	Lymph node metastasis	Medium-Low	35.59	0.08	11.3

Gil J. et al. | Malignant melanoma proteogenomics

P107	75	Male	PT3A	UNCLASS	V600K	DM107	Spleen metastasis	Medium-High	47.70	8.67 YES	
P110	81	Female	N/A	N/A	N/A	NT110	Non-tumor	Medium-Low	0	0 N/A	
P110	81	Female	PT3B	SSM	V600K	PT110	Primary tumor	Medium-High	44.01	3.57 N/A	
P110	81	Female	PT3B	SSM	V600K	LN146	Lymph node metastasis	Medium-High	52.96	17.27 NO	
P115	82	Female	N/A	N/A	N/A	NT115	Non-tumor	Medium-Low	0	0 N/A	
P115	82	Female	N/A	N/A	WT	CM115	Cutaneous metastasis	Medium-Low	71.49	3.17 NO	
P116	47	Female	N/A	UNCLASS	WT	DM116	Breast metastasis	Medium-Low	29.47	1 YES	
P164	51	Male	N/A	SSM	V600E	CM164	Cutaneous metastasis	High	26.13	6.03 NO	

 Table S2 Summary of average (± standard variation) of variants (SNPs, indels) identified in WES data of 60 tumors.

Type of mutations	Somatic	Germline
SNPs A>C and T>G	4361 ± 716	872 ± 29
SNPs A>G and T>C	4573 ± 635	6104 ± 119
SNPs A>T and T>A	11681 ± 1916	738 ± 41
SNPs C>A and G>T	9497 ± 1622	1158 ± 62
SNPs C>G and G>C	5585 ± 888	1325 ± 42
SNPs C>T and G>A	10479 ± 1593	8818 ± 299
All SNPs	46177 ± 7162	19015 ± 547
indels	57423 ± 10369	256 ± 19
All variants	113609 ± 19156	19271 ± 256

Table S3. List of genes identified as a hots	pot in melanoma WES data requiring presence	ce of the hot spot in 20 out of the 6	50 analyzed samples.

Ensembl gene ID	chromosome	start position	gene symbol	description	number of significant samples
ENSG00000185519	1	16057769	FAM131C	family with sequence similarity 131 member C [Source:HGNC Symbol;Acc:HGNC:26717]	27
ENSG00000142794	1	21440128	NBPF3	NBPF member 3 [Source:HGNC Symbol;Acc:HGNC:25076]	39
ENSG00000132849	1	61742477	PATJ	PATJ crumbs cell polarity complex component [Source:HGNC Symbol;Acc:HGNC:28881]	31
ENSG00000122417	1	86346824	ODF2L	outer dense fiber of sperm tails 2 like [Source:HGNC Symbol;Acc:HGNC:29225]	28
ENSG00000116299	1	109113679	ELAPOR1	endosome-lysosome associated apoptosis and autophagy regulator 1 [Source:HGNC Symbol;Acc:HGNC:29618]	26
ENSG00000237975	1	152168125	FLG-AS1	FLG antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:27913]	28
ENSG00000244414	1	196819731	CFHR1	complement factor H related 1 [Source:HGNC Symbol;Acc:HGNC:4888]	26
ENSG00000119285	1	236549005	HEATR1	HEAT repeat containing 1 [Source:HGNC Symbol;Acc:HGNC:25517]	43
ENSG00000197591	1	247840928	OR11L1	olfactory receptor family 11 subfamily L member 1 [Source:HGNC Symbol;Acc:HGNC:14998]	33
ENSG00000177462	1	247920252	OR2T8	olfactory receptor family 2 subfamily T member 8 [Source:HGNC Symbol;Acc:HGNC:15020]	37
ENSG00000224521	1	248548756	AC098483.1	novel transcript	35
ENSG00000177151	1	248636356	OR2T35	olfactory receptor family 2 subfamily T member 35 [Source:HGNC Symbol;Acc:HGNC:31257]	23
ENSG00000187701	1	248649838	OR2T27	olfactory receptor family 2 subfamily T member 27 [Source:HGNC Symbol;Acc:HGNC:31252]	32
ENSG00000134463	10	11742366	ECHDC3	enoyl-CoA hydratase domain containing 3 [Source:HGNC Symbol;Acc:HGNC:23489]	48
ENSG00000204740	10	19048801	MALRD1	MAM and LDL receptor class A domain containing 1 [Source:HGNC Symbol;Acc:HGNC:24331]	26
ENSG00000148513	10	37125725	ANKRD30A	ankyrin repeat domain 30A [Source:HGNC Symbol;Acc:HGNC:17234]	25
ENSG00000197893	10	113588714	NRAP	nebulin related anchoring protein [Source:HGNC Symbol;Acc:HGNC:7988]	42
ENSG00000288107	10	133565797	AL731769.2	novel transcript, antisense to FRG2Band SYCE1	50
ENSG00000185627	11	236966	PSMD13	proteasome 26S subunit, non-ATPase 13 [Source:HGNC Symbol;Acc:HGNC:9558]	52
ENSG00000184956	11	1012823	MUC6	mucin 6, oligomeric mucus/gel-forming [Source:HGNC Symbol;Acc:HGNC:7517]	60
ENSG00000196565	11	5253188	HBG2	hemoglobin subunit gamma 2 [Source:HGNC Symbol;Acc:HGNC:4832]	38
ENSG00000239920	11	5254392	AC104389.5	novel transcript	39
ENSG00000132256	11	5663195	TRIM5	tripartite motif containing 5 [Source:HGNC Symbol;Acc:HGNC:16276]	40
ENSG00000271758	11	7704628	AC044810.3	novel transcript, sense overlapping OR5P2, OR5P3 and OR5P1P	20
ENSG00000255071	11	18231423	SAA2-SAA4	SAA2-SAA4 readthrough [Source:HGNC Symbol;Acc:HGNC:39550]	25
ENSG00000172199	11	56375624	OR8U1	olfactory receptor family 8 subfamily U member 1 [Source:HGNC Symbol;Acc:HGNC:19611]	60
ENSG00000174914	11	56699095	OR9G1	olfactory receptor family 9 subfamily G member 1 [Source:HGNC Symbol;Acc:HGNC:15319]	60
ENSG00000197658	11	63079940	SLC22A24	solute carrier family 22 member 24 [Source:HGNC Symbol;Acc:HGNC:28542]	35
ENSG00000173153	11	64305497	ESRRA	estrogen related receptor alpha [Source:HGNC Symbol;Acc:HGNC:3471]	27
ENSG00000137675	11	102691487	MMP27	matrix metallopeptidase 27 [Source:HGNC Symbol;Acc:HGNC:14250]	23
ENSG00000182634	11	124036013	OR10G7	olfactory receptor family 10 subfamily G member 7 [Source:HGNC Symbol;Acc:HGNC:14842]	25

Gil J. et al. | Malignant melanoma proteogenomics

Instrument 1 Use bases Anstrument Production Science Production Sc						
HOMEONOLINIS 0.1 BADDA Applia appli	ENSG00000120451	11	130866250	SNX19	sorting nexin 19 [Source:HGNC Symbol;Acc:HGNC:21532]	21
90500000000000000000000000000000000000	ENSG00000111704	12	7787794	NANOG	Nanog homeobox [Source:HGNC Symbol;Acc:HGNC:20857]	52
INSCOUNDING 01 100-0000 100 product in grant state 2 hours (Month State) 0.5 INSCOUNDING 12 400000 400000 400000 4000000 400000 400000 400000000 4000000000000000000000000000000000000	ENSG00000166535	12	8822621	A2ML1	alpha-2-macroglobulin like 1 [Source:HGNC Symbol;Acc:HGNC:23336]	26
INSCOUNDING 01 100-0000 100 product in grant state 2 hours (Month State) 0.5 INSCOUNDING 12 400000 400000 400000 4000000 400000 400000 400000000 4000000000000000000000000000000000000	ENSG0000255641	12	10412312	AC068775.1	novel protein	58
DeSDECORDING Q.12 Q.02144 URD21 Instants for spans hand 2 Socies MDX Second/CH2D12401. Q.13 DESDECORDING Q.12 Q.02140 C.01179 C.Cand THY THERE & Discretific X EnroldsCH2D1242. Q.13 DESDECORDING Q.12 Q.02140 F.MART DesDECORDING CONTROL CONTRO						
0 0						
0.0500000000000 10.10 4.400.7000 C. Lag of the related Planeration Complex/SecU.221 4.7 PRESEDUDITIONE 13.1 10.0000000000 13.1 10.0000000000 13.1 10.00000000000 13.1 10.00000000000 13.1 10.000000000000 13.1 10.00000000000 13.1 10.000000000000 13.1 10.000000000000 13.1 10.00000000000000000000000000000000000						
UB050000012697 Init Aleady at a provide protect prote						
info@cond_shifty 1.1 2.0000000000000000000000000	ENSG00000240654	13	24307166	C1QTNF9	C1q and TNF related 9 [Source:HGNC Symbol;Acc:HGNC:28732]	29
195000001191 144 18103812 COLAG configure property aging 1 and 11 (Source) SUC Symbol Act SUC Symbol Act SUC Symbol Act SUC SYMD SUC	ENSG00000102699	13	24420931	PARP4	poly(ADP-ribose) polymerase family member 4 [Source:HGNC Symbol;Acc:HGNC:271]	47
195000001191 144 18103812 COLAG configure property aging 1 and 11 (Source) SUC Symbol Act SUC Symbol Act SUC Symbol Act SUC SYMD SUC	ENSG00000151846	13	25096136	PABPC3	poly(A) binding protein cytoplasmic 3 [Source:HGNC Symbol;Acc:HGNC:8556]	57
INSEGURD 112 14 20210 Control of Con	ENSG00000134871	13	110305812	COL4A2	collagen type IV alpha 2 chain [Source:HGNC Symbol:Acc:HGNC:2203]	21
656500001321 14 20221710 00311-6 ordstory recents in sub sub system in the one follower sub Construction System in the						
FISSO000011000 144 29840005 ORES athering responsible from some family is undering from the Cliff Cyberold Activity Costs 20 DESCO00011460 15 233508 60.066.2 genen for them the 21 Source 100C symbolics (1960-C2053) 43 DESCO00011470 15 73.5506 420.0017 Advances 1000-0017 44 DESCO00011470 16 113.306 CACNA11 Advances 1000-0017 100 DESCO00011737 16 113.306 CACNA11 CACNA11 Descention Control Contro Control Control Control Contro Control Control Control						
04500000000000000000000000000000000000						
HostGOOD1450 15 77.9700 COMM2 Build State						
195000019378 15 1772306 ADAM 772 ADAM realbagedings with incursing plant functions 1 mod 17 Super setter Superior AEM Symbols. PLONE 221 095000019377 16 123007 TFAM1 Unsuper setter Amaze Simology and the setter Amaze Simology and Amaze	ENSG00000185567	14	104937244	AHNAK2	AHNAK nucleoprotein 2 [Source:HGNC Symbol;Acc:HGNC:20125]	44
INSTRUMENT IS IS CALMANT calama vision and subart spinals in [Source:ROK_VPMDACE:NDC.12070] 22 INSTRUMENTS 15 13.0170 TSAN Trypics alphast [Source:ROK_VPMDACE:NDC.12070] 39 INSTRUMENTS 15 14.566 17.500 Trypics alphast [Source:ROK_VPMDACE:NDC.12070] 39 INSTRUMENTS 15 5500.2551 CG1 Calamatic algorization (Source:ROK_VPMDACE:NDC.12171] 30 INSTRUMENTS 15 5500.2551 CG1 Calamatic algorization (Source:ROK_VPMDACE:NDC.12171] 31 INSTRUMENTS 15 7500.2553 PC01 Polycipital Intel Instruments [Source:ROK_VPMDACE:NDC.21716] 40 INSTRUMENTS 17 2124672 MAV20 antegen-activate protein formal trainer Instrument CRC VPMDACE:NDC.2011] 40 INSTRUMENTS 13 14007714 A10 Materia distrument and protein trainer Instrument CRC VPMDACE:NDC.2011] 41 INSTRUMENTS 13 144114 AA27 1444 Materia distrument and protein trainer Instrument CRC VPMDACE:NDC.20161] 41 INSTRUMENTS 13 1444 AA27	ENSG00000174450	15	23439038	GOLGA6L2	golgin A6 family like 2 [Source:HGNC Symbol;Acc:HGNC:26695]	39
ENSDOOD 150 150000 150000 1500000 1500000 1500000 15000000 15000000000000000000000000000000000000	ENSG00000136378	15	78759206	ADAMTS7	ADAM metallopeptidase with thrombospondin type 1 motif 7 [Source:HGNC Symbol;Acc:HGNC:223]	45
Inspace 14.3 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.4017 13.5017 1	ENSG00000196557	16	1153106	CACNA1H		22
Instrume 13 13403 17901 instrume delta LSource HOC SympoleActINOC14171 1991 005000002102 16 144686 PT44 perturine Reserve HOC SympoleActINOC14171 25 105000001105 16 5877131 C017 carboxyloreraes [Nourse HOC SymboleActINOC14313] 21 10500001105 16 5877131 C017 Classes Control 21 10500001105 16 597918 Classes Control 21						
IPS000021582 15 134988 PTM pertraint [SucceMpNC SymbAccHONC 1471] P53 DPS000011386 16 SS02151 CCI carbony/eterminas [SucceMPNC SymbAccHONC 1472] 56 DPS0000113767 16 S970713 OP72 gltAam-calabactik transminas 2 BourceMPC SymbAccHONC 2008] 71 DPS0000117761 18 7792788 PTM13 paywysth 18e 3 Transmitter regree protein thans intera 2 BourceMPC SymbAccHONC 2008] 60 DPS0000011761 21 2157877 KRU2 paywysth 18e 3 Transmitter regree protein thans intera 2 BourceMPC SymbAccHONC 2007] 53 DPS0000011764 18 S182427 AVR2 appaysth rett/inpa member 12 BourceMPC SymbAccHONC 2007] 53 DPS0000011765 18 199395 PVM paybath/inpa/member 12 Bource MPC SymbAccHONC 2007] 53 DPS0000011765 18 199395 PVM paybath/inpa/member 2 Bource MPC SymbAccHONC 2007] 53 DPS0000017765 18 499395 PVM paybath/inpa/member 2 Bource MPC SymbAccHONC 2007] 53 DPS0000017765 18 4993935 PVM phoone Power PMC SymbAb						
INNECODOURSHAME 16 SIMULTA Control (Statement Control						
IPHOCOND27:166 161 5470731 COT2 g/g/gramma g/g/gramma <thg gramma<="" th=""></thg>		16			pentraxin 4 [Source:HGNC Symbol;Acc:HGNC:14171]	
0450000017122 15 04997200 CLELIAN C-type tects in domain family: all member / A fource 1004/C symbols/cc1004/C2108 17 0450000017123 17 7223938 PN013 polysmith IIIs 3, transient member / a fource 1004/C symbols/cc1004/C2108 60 0450000014153 17 2239737 COULT potassium immerity recting activate of poten binates in the 21 Source 1004/C symbols/cc1004/C2108 60 0450000014168 17 24097716 AVR10 potassium immerity recting activate family fource 1004/C symbols/cc1004/C2108 41 0450000014076 18 14865200 Sold activate family fource 1004/C symbols/cc1004/C2108 43 0450000014076 18 4880127 Ark2 gotaplashiphionate gyran activate family fource 1004/C symbols/cc1004/C2108 43 0450000014076 19 402338 CNV2 Colpoint 12 Source 1004/C symbols/cc1004/C2108 55 0450000014084 19 986486 FUT functs find family fource 1004/C symbols/cc1004/C2108 26 045000001476 19 940338 94 9604387 functs find family fource 1004/C symbols/cc1004/C1301 24 04500000139388	ENSG0000198848	16	55802851	CES1	carboxylesterase 1 [Source:HGNC Symbol;Acc:HGNC:1863]	26
04560000277481 US P2929011 IIII Strainert negets premiul channel interacting SummeHild Symbol AccHORC32010 94 0550000034185 17 2137837 IKUNI2 potossum inwardly rectrlying channel subsame SISsore-HIRS Symbol AccHORC42081 60 05600000316756 18 9497716 KR140 katati AQ Donce-HIRS Symbol AccHORC45081 60 0560000236756 18 94981716 KR140 data in AQ Donce-HIRS Symbol AccHORC30101 53 0560000236756 18 9498174 A/P.2 dpits hase 2 Donce-HIRS Symbol AccHORC301631 31 0560000236756 18 9498174 A/P.2 dpits hase 2 Donce-HIRS Symbol AccHORC301631 32 05600000236757 19 3000419 GRN2 cgits in Age 2 Conce-HIRS Symbol AccHORC30291 23 0560000023677 19 450230 PLN4 prelipin 1 Source-HIRS Symbol AccHORC3021 35 0560000013678 19 359328 277858 Bit Engreprelins 35 Source-HIRS Symbol AccHORC3021 35 056000013677 19 440023 AccHOR 35 AccHOR 35 36 05600000126	ENSG00000125166	16	58707131	GOT2	glutamic-oxaloacetic transaminase 2 [Source:HGNC Symbol;Acc:HGNC:4433]	21
04560000277481 US P2929011 IIII Strainert negets premiul channel interacting SummeHild Symbol AccHORC32010 94 0550000034185 17 2137837 IKUNI2 potossum inwardly rectrlying channel subsame SISsore-HIRS Symbol AccHORC42081 60 05600000316756 18 9497716 KR140 katati AQ Donce-HIRS Symbol AccHORC45081 60 0560000236756 18 94981716 KR140 data in AQ Donce-HIRS Symbol AccHORC30101 53 0560000236756 18 9498174 A/P.2 dpits hase 2 Donce-HIRS Symbol AccHORC301631 31 0560000236756 18 9498174 A/P.2 dpits hase 2 Donce-HIRS Symbol AccHORC301631 32 05600000236757 19 3000419 GRN2 cgits in Age 2 Conce-HIRS Symbol AccHORC30291 23 0560000023677 19 450230 PLN4 prelipin 1 Source-HIRS Symbol AccHORC3021 35 0560000013678 19 359328 277858 Bit Engreprelins 35 Source-HIRS Symbol AccHORC3021 35 056000013677 19 440023 AccHOR 35 AccHOR 35 36 05600000126	ENSG00000157322	16	69950705	CLEC18A		27
HISSO00034132 IT 1234572 MM223 mtogen-activated protein knase kinase 1500-restR05 symbol.Act:NR0C 883] 60 HISSO0003488 IT 4495716 KE1012 petasiani muscif years fully simular land muscle for the Symbol.Act:NR0C 8903 53 HISSO00034989 III 4495716 KE140 solut arminy is member 4605 Symbol.Act:NR0C 30051 33 HISSO00031979 IIII IIII 1199566 CM121 petasiani muscle symbol.act:NR0C Symbol.act:NR0C 12061 29 HISSO00031979 IIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII						
PISSC0000184183 17 2173/877 KCUL2 potasiani movely restring channel subfamily. Immetry EdS Symbol.Acc:HOK:23801 60 FISSC0000236995 18 1109956 SIC3364 Subte carrier family.35 member 64 [Source:HOK:Symbol.Acc:HOK:31031] 41 FISSC00002369756 18 63403255 PAPI abla barrier family.35 member 64 [Source:HOK:Symbol.Acc:HOK:31031] 43 FISSC00002369756 18 63403255 PAPI abla barrier family.35 member 64 [Source:HOK:Symbol.Acc:HOK:23861] 29 FISSC0000236976 18 63403255 PAPI abla barrier family.35 member 64 [Source:HOK:Symbol.Acc:HOK:23867] 29 FISSC0000116326 19 1000419 Ginna Sa glutamate isotropic receptor MOA byte subant 38 [Source:HOK:Symbol.Acc:HOK:2381] 23 FISSC0000116326 19 3961529 ZY for associated [Source:HOK:Symbol.Acc:HOK:2393] 23 FISSC0000238378 19 4901527 XC00357 35 Source:HOK:Symbol.Acc:HOK:2301] 40 FISSC0000238379 19 4901527 XC00357 36 36 35 FISSC0000238379 19 <						
HISGO00001488 11 4997716 KET40 Invariant Glisoure-HIGK Symboly-CHORC-37071 35 ENGOD00015976 18 1189786 SCI3564 solute carrier fimily 35 number 64 [Source-HIGK-CS006] 33 ENGOD00015976 18 6140225 PIGN gho Immer 25 [Source-HIGK-Symboly-CHORC-2006] 33 ENGOD00015976 18 6140225 PIGN gho Immer 26 [Source-HIGK-Symboly-CHORC-3068] 29 ENGOD00016976 19 1000419 GBIN38 gaturante interrigent WIAN bystubuits 38 [Source-HIGK Symboly-CHORC-1368] 29 ENGOD00015776 19 400110 PUN peripinal 4 [Source-HIGK Symboly-CHORC-1376] 23 ENGOD00015776 19 400120 muth 18 Foresthick Symboly-CHORC-2303] 23 ENGOD00013778 19 3601207 Accoss71.1 muth 18 Foresthick Symboly-CHORC-20012 25 ENGOD00013776 19 5492202 LIBA2 Endocyte Immungboluit In erceptor A1 [Source-HIGK Symboly-CHORC-2003] 25 ENGOD00013776 19 5492720 LIBA2 Endocyte Immungboluit In erceptor A1 [Source-HIGK Symboly-						
HYSG000023839 118 1190996 SCL5564 Jobite carrer family 35 methor GR Symbol/Acc:HORC.2003] 41 HYSG0000138796 18 58481247 ALPC2 Balha kinase 2 (Source HORC Symbol/Acc:HORC.20055) 33 HYSG0000116023 19 1000419 GRINBS glutamate ion/tropic receptor MIOA type subunits [Source HORC Symbol/Acc:HORC.2156] 29 HYSG0000167676 19 4522180 PUH4 perilipin 4 [Source HORC Symbol/Acc:HORC.2156] 24 HYSG00000167676 19 4522180 PUH4 perilipin 4 [Source HORC Symbol/Acc:HORC.2159] 24 HYSG00000167676 19 4522180 PUH4 perilipin 4 [Source HORC Symbol/Acc:HORC.2159] 24 HYSG0000018747 19 585326 20175 ffuorsparse 25 HYSG0000018747 19 4001277 A00083711 morch 15 cell Symbol/Acc:HORC.23037] 43 HYSG0000018767 19 5457202 ULRA2 feudoryte mmrunoglobulin like receptor A1 [Source-HORC Symbol/Acc:HORC.2407] 25 HYSG0000018767 19 547202 ULRA2 feudoryte mmrunoglobulin like receptor A1 [Source-HORC S						
ENSCODUNTERS IBI 5981247 AIP2 algas have 2 Source 540C Symbols/cc:160C:20501 B3 ENSCODUNTERS IBI 6390235 PION phosphatiophics idea INScorre 540C Symbols/cc:160C:20571 29 ENSCODUNTERS IBI 1000413 GRINBA glubarnate lootopic receptor NMOA type subunt BI [Surce FMOC Symbols/cc:160C:20301] 23 ENSCODUNTERS IBI 9402130 PUIN4 perlipin 4 [Surcer-160C Symbols/cc:160C:20301] 23 ENSCODUNTERS IBI 9888844 MUCIS micro Inscreption Symbols/cc:160C:20301] 24 ENSCODUNTERS IBI 9888844 MUCIS micro Inscreption Symbols/cc:160C:20301] 24 ENSCODUNTERS IBI 9801827 ZMYS88 Inc finger protein S& [Source:160C Symbols/cc:160C:6031] 28 ENSCODUNTERS IBI 248343 Inscreptorein SA [Source:160C Symbols/cc:160C:6031] 25 ENSCODUNTERS IBI 2400252 IBIA Networe Inscreptor II [Source:160C Symbols/cc:160C:6031] 25 ENSCODUNTERS IBIA 2407253 IBIA Networe Inscreptor II [Source:160C Symbols/cc:160C:6031] <	ENSG00000204889	17	40977716	KRT40	keratin 40 [Source:HGNC Symbol;Acc:HGNC:26707]	35
ENSCOUNDITY-561 131 61902-555 PPION photophalphildpinesting (pken anchor biosynthesis class) P23 ENSCOUNDIT-602 19 1000413 GRN88B glutamate lonotropic receptor NNDA type subunt 38 (Source HONC SymbolAccHONC-16768) 29 ENSCOUNDIT-664 19 1005566 CNN2 cation 11 (Source HONC SymbolAccHONC-2156) 56 ENSCOUNDIT-664 19 4402130 PUIM pentigin 14 Source HONC SymbolAccHONC-23931 23 ENSCOUNDIT-664 98 884884 MUCL much 15, cell suffice associated [SourceHONC SymbolAccHONC-1582] 40 ENSCOUNDIT-664 98 38016232 2NHS8 2NHS8 ZNHS8 2NHS8 ENSCOUNDIT-664 19 4001127 10 SourceHONC SymbolAccHONC-28537] 40 ENSCOUNDIT-664 19 5473720 LIBA1 Inuclocyte immunoglobulin like receptor A1 [SourceHONC SymbolAccHONC-28547] 43 ENSCOUNDIT-664 19 5575914 LIBA1 Inuclocyte immunoglobulin like receptor A1 [SourceHONC SymbolAccHONC-2857] 43 ENSCOUNDIT-664 19 55759514 BFPLAA ref trecr	ENSG00000236396	18	11609596	SLC35G4	solute carrier family 35 member G4 [Source:HGNC Symbol;Acc:HGNC:31043]	41
Integration Image End Section Processing	ENSG00000198796	18	58481247	ALPK2	alpha kinase 2 [Source:HGNC Symbol;Acc:HGNC:20565]	33
INSCONDUIGNUM 199 100419 GENBS glutamate isontropic respirat NUMA type submoleka:HGNC2156] 29 ENSCONDUIGNES 19 11025566 CNN2 calpoint 2 [Source:HGNC Symboleka:HGNC2156] 56 ENSCONDUISNES 19 4560210 PLIN4 perlipin 1 [Source:HGNC Symboleka:HGNC2156] 23 ENSCONDUISNES 19 588884 HUTS fucury transferrase 5 [Source:HGNC Symboleka:HGNC2582] 55 ENSCONDUISNES 19 3898384 MUC16 much IG. edi sufface associated [Source:HGNC Symboleka:HGNC2582] 40 ENSCONDUISNES 19 54921977 747534 incr finger protein 586 [Source:HGNC Symboleka:HGNC2633] 43 ENSCONDUISNES 19 5457250 LILBA2 leukocyte immunogibubin like receptor A2 [Source:HGNC Symboleka:HGNC:GGS] 54 ENSCONDUISNES 19 5457358 LILBA1 leukocyte immunogibubin like receptor A2 [Source:HGNC Symboleka:HGNC:GGS] 54 ENSCONDUISNES 19 5576913 REFHAA1 ref finger protein like A5 [Source:HGNC Symboleka:HGNC:GGS] 54 ENSCONDUISNES 2 20757515 HIRBA2	ENSG00000197563	18	61905255	PIGN		29
EHSGO00005666 19 102556 CM2 calpoin 2 Source-HOK Symbol/Act-HOK-2393] 56 ENSGO000167676 19 4502180 PUN4 pertipin 4 [Source-HOK Symbol/Act-HOK-2393] 23 ENSGO000167676 19 566826 FUT5 fuoxiting function associated [Source-HOK CSYmbol/Act-HOK-2392] 40 ENSGO00026877 19 40801277 AC00537.1 non-ting periodin SG [Source-HOK Symbol/Act-HOK-2392] 40 ENSGO00026878 19 52429187 ZWF58 anic finger protein SG [Source-HOK Symbol/Act-HOK-2393] 43 ENSGO00016874 19 54572920 LILRA2 leukocyte immunglobulin like receptor A2 [Source-HOK Symbol/Act-HOK-2603] 25 ENSGO00016877 19 54617158 LILRA1 leukocyte immunglobulin like receptor A2 [Source-HOK Symbol/Act-HOK-2603] 25 ENSGO000167765 19 5505033 AC011673 ref finger protein imacrybulin like receptor A1 [Source-HOK Symbol/Act-HOK-2609] 26 ENSGO000126766 2 2076526 FAM228 family with sequence similarit 228 embers to Source-HOK Symbol/Act-HOK-2649] 21 ENSGO00021586 2 2						-
INSCODUNITATION 19 4902180 PUIN4 perflips 4 [source HONC Symbol/Acc:HONC-20193] 23 ENSCODUNITATION 19 5865826 FUT5 futosyttensferaes 5 [Source HONC Symbol/Acc:HONC-2016] 24 ENSCODUNITATION 19 884844 MUCL6 mucin IL, cell synche associated [Source HONC Symbol/Acc:HONC-2016] 24 ENSCODUNITATION 884844 MUCL6 mucin IL, cell synche associated [Source HONC Symbol/Acc:HONC-2017] 40 ENSCODUNITATION 40081127 10 40081127 10 5457217 43 ENSCODUNITATION 11 ILLBAL Inducry terminanglobulin like receptor AL [Source-HONC Symbol/Acc:HONC-6602] 25 ENSCODUNITATION 19 5457321 LILBAL Inducry terminanglobulin like receptor AL [Source-HONC Symbol/Acc:HONC-6602] 26 ENSCODUNITATION 19 5459318 LILBAL Inducry terminanglobulin like receptor AL [Source-HONC Symbol/Acc:HONC-6602] 26 ENSCODUNITATION 19 54693282 LILBAL ret finger protein like AL [Source-HONC Symbol/Acc:HONC-6377] 56 ENSCODUNITATION 55568 FMAT288 family wi						
ENSG0000130383 19 SBS5826 FUTS fucosyltransferase S [Source:HGN: Symbol/Acc:HGN:C4016] 24 ENSG0000134143 19 884844 MUC16 mucin 16, cell surface associated [Source:HGN: Symbol/Acc:HGN:C15582] 40 ENSG0000134343 19 48011297 AC00857.7 19 40011297 AC00857.1 noreline for Statuse Stat	ENSG0000064666	19	1026586	CNN2	calponin 2 [Source:HGNC Symbol;Acc:HGNC:2156]	56
ENSG0000181143 19 8848844 MUC16 mucin 16, cell surface associated [Source:HGNC Symbol/Acc:HGNC:15582] 55 ENSG000018453 19 3661329 2VF588 zinc finger protein 58 (Source:HGNC Symbol/Acc:HGNC:25382) 40 ENSG000018977 19 440801297 2NF534 zinc finger protein 54 (Source:HGNC Symbol/Acc:HGNC:26337) 43 ENSG000018978 19 5457320 LILRA1 leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol/Acc:HGNC:6602] 25 ENSG000022525 19 54507320 LILRA1 leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol/Acc:HGNC:6602] 26 ENSG0000225252 19 55759014 RPFLAA ret finger protein like A1 [Source:HGNC Symbol/Acc:HGNC:6602] 21 ENSG000022562 2 24075526 FAM2288 family with sequence similarity 228 member 8 [Source:HGNC Symbol/Acc:HGNC:24736] 21 ENSG000021562 2 21313134 ANR036 ankyrin repeat domin an 6 [Source:HGNC Symbol/Acc:HGNC:24736] 21 ENSG0000157976 2 97113133 ANR036 ankyrin repeat domin an 5 [Source:HGNC Symbol/Acc:HGNC:24736] 23 ENS						
ENSG000019843 19 36916329 2NF568 2inc finger protein 568 [Source:HGN: Symbol;Acc:HGN::25392] 40 ENSG0000268/93 19 45001297 AC00837.1 78734 2inc finger protein 534 [Source:HGN::Symbol;Acc:HGN::C5337] 43 ENSG0000198633 19 54721920 LIBA2 leukocyte immunoglobulin like receptor A1 [Source:HGN: Symbol;Acc:HGN::C603] 55 ENSG000019974 19 54637158 LIBA1 leukocyte immunoglobulin like receptor A1 [Source:HGN: Symbol;Acc:HGN::G605] 54 ENSG000012972 19 54637158 LIBB1 leukocyte immunoglobulin like receptor B1 [Source:HGN: Symbol;Acc:HGN::G605] 54 ENSG0000226283 19 55759118 RFPLA1 ret finger protein like A1 [Source:HGN: Symbol;Acc:HGN::G449] 32 ENSG000022928 19 55759118 RFPLA1 ret finger protein like A1 [Source:HGN: Symbol;Acc:HGN::G447] 56 ENSG000012926 2 2007556 FAM2288 family with sequence simalary 228 membol;Acc:HGN::G407] 21 ENSG000012938 2 1301174 AVM8036 anlyrin repeat family member X1 [Source:HGN: Symbol;Acc:HGN::C4736] 37	ENSG00000167676	19	4502180	PLIN4	perilipin 4 [Source:HGNC Symbol;Acc:HGNC:29393]	23
INSG0000268797 19 40801297 AC008537.1 novel protein 28 ENSG000026833 19 52429187 ZW534 zinc finger protein 534 [Source+HGKC Symbol,Acc+HGKC.6603] 55 ENSG000029898 19 54572920 LLRA1 leukocyte immungdobulin like receptor A1 [Source+HGKC Symbol,AccHGKC.6603] 25 ENSG000029727 19 54567138 LLRB1 leukocyte immungdobulin like receptor A1 [Source+HGKC Symbol,AccHGKC.6605] 54 ENSG0000226726 19 5506133 AC011476.3 novel transcript, antisense to RDH13 and GP6 26 ENSG0000226726 19 5575014 RPFLAA ret finger protein like A4 [Source+HGKC Symbol,AccHGKC.54736] 22 ENSG0000229292 19 5575018 RPFLAAL ret finger protein like A4 [Source+HGKC Symbol,AccHGKC.24736] 21 ENSG0000135086 2 13013745 TURA3E tubuin alpha a E [Source+HGK Symbol,AccHGKC.24736] 37 ENSG0000152086 2 13013745 TURA3E tubuin alpha a E [Source+HGK Symbol,AccHGKC.24736] 30 ENSG0000152086 2 13031745 TURA3E tubuin a						
ENSG0000198633 19 52429187 ZNF534 zinc finger protein 534 [Source-HGNC Symbol,Acc.HGNC.26337] 43 ENSG000029998 19 5457220 LILRA2 leukocyte immunglobulin like receptor A2 [Source-HGNC Symbol,Acc.HGNC.6603] 55 ENSG000014971 19 54617158 LILRB1 leukocyte immunglobulin like receptor A1 [Source-HGNC Symbol,Acc.HGNC.6602] 25 ENSG0000267265 19 55061133 AC011476.3 move transcript, antisene to R0113 and GP6 26 ENSG0000229328 19 555760118 RFPLAAL ref finger protein like A1 [Source-HGNC Symbol,Acc:HGNC.5417] 56 ENSG0000229302 19 55760118 RFPLAAL ref finger protein like A1 [Source-HGNC Symbol,Acc:HGNC.24736] 21 ENSG0000229302 19 55760118 RFPLAAL ref finger protein like A1 [Source-HGNC Symbol,Acc:HGNC.24736] 21 ENSG000012976 2 2076526 FAM2288 family with sequence similarity 228 member 8 [Source-HGNC Symbol,Acc:HGNC.24736] 37 ENSG0000129730 2 130191745 TUBA3E tubulin lapha 3 E [Source-HGNC Symbol,Acc:HGNC.214027] 27 ENSG0000158779	ENSG00000130383	19	5865826	FUT5	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016]	24
ENSG0000198633 19 52429187 ZNF534 zinc finger protein 534 [Source-HGNC Symbol,Acc:HGNC.26337] 43 ENSG000029998 19 5457320 LILRA2 leukocyte immunglobulin like receptor A1 [Source-HGNC Symbol,Acc:HGNC.6603] 55 ENSG0000104974 19 54593528 LILRA1 leukocyte immunoglobulin like receptor A1 [Source-HGNC Symbol,Acc:HGNC.6602] 25 ENSG00001292636 19 55506133 AC011476.3 novel transcript, anisense to RDH13 and GP6 26 ENSG00002292838 19 55750118 RFPLAAL reft finger protein like A1 [Source-HGNC Symbol,Acc:HGNC.45477] 56 ENSG0000229292 19 55769118 RFPLAAL reft finger protein like A1 [Source-HGNC Symbol,Acc:HGNC.24736] 21 ENSG0000125076 2 2076526 FAM2288 family with sequence similarity 228 member B [Source-HGNC Symbol,Acc:HGNC.24736] 21 ENSG0000153976 2 130191745 TUBA3E tubulin alpha 3 E [Source-HGNC Symbol,Acc:HGNC.24736] 30 ENSG0000154979 21 23585565 MRP139 movel protein, SIRPB1-SIRPD readthrough 29 ENSG000001549719 21	ENSG00000130383 ENSG00000181143	19 19	5865826 8848844	FUT5 MUC16	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582]	24 55
ENSG00000239998 19 54572920 LILRA2 leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol.Acc:HGNC:6603] 55 ENSG0000104574 19 54593582 LILRA1 leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol.Acc:HGNC:6603] 25 ENSG0000104574 19 546171258 LILRA1 leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol.Acc:HGNC:6605] 54 ENSG0000129232 19 55759014 RFPLAA1 ret finger protein like 4A [Source:HGNC Symbol.Acc:HGNC:1649] 32 ENSG0000219262 2 24076526 FAM2288 family wth sequence similarity 238 member 8 [Source:HGNC Symbol.Acc:HGNC:4187] 56 ENSG0000219266 2 130191745 TUBA3E tubulin alpha 3e [Source:HGNC Symbol.Acc:HGNC:20765] 37 ENSG0000150368 2 13375679 MRCH2A maetro heat like repeat family member 2A [Source:HGNC Symbol.Acc:HGNC:20765] 37 ENSG0000015086 2 130191745 TUBA3E tubulin alpha 3e [Source:HGNC Symbol.Acc:HGNC:20765] 37 ENSG0000015284 2 23375679 MRCH2A maetro heat like repeat family member 2A [Source:HGNC Symbol.Acc:HGNC:20765] 30	ENSG0000130383 ENSG0000181143 ENSG0000198453	19 19 19	5865826 8848844 36916329	FUT5 MUC16 ZNF568	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392]	24 55 40
ENSG0000104974 19 54593582 ILIRA1 leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] 25 ENSG000027256 19 5506133 AC011476.3 novel transcript, antisene to RDH1 and GP6 26 ENSG0000225258 19 55575014 RFFL4A1 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:1649] 32 ENSG0000225922 19 55769118 RFFL4A1 ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:4347] 56 ENSG000025926 2 24075526 FFAM2288 family with sequence similarity 228 member 8 [Source:HGNC Symbol;Acc:HGNC:4736] 21 ENSG000025086 2 130191745 TUBA3E tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:2736] 30 ENSG000025081 20 1357671 MGND2A meator heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:2736] 30 ENSG0000015808 20 1340144 ALU49634.2 mover thorein, SIRBE1-SIRP teadthrough 29 ENSG0000015804 21 44497893 TSFEAR thrombospondin type lamin G domain and EAK repeat SIGNC:#HGNC:HGNC:14027] 27 ENSG0000017584	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797	19 19 19 19	5865826 8848844 36916329 40801297	FUT5 MUC16 ZNF568 AC008537.1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein	24 55 40 28
ENSG0000164972 19 54617158 LILRB1 leukocyte immunglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] 54 ENSG0000257265 19 55066193 AC011476.3 novel transcript, antisense to RDH3 and GP6 26 ENSG0000252626 19 55759118 RFPL4AL ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] 56 ENSG0000219222 19 55769118 RFPL4AL ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] 56 ENSG0000219262 2 20075526 FAM2288 family with sequence similarity 228 member 8 [Source:HGNC Symbol;Acc:HGNC:24736] 21 ENSG0000152086 2 130191745 TUBA3E tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24793] 56 ENSG00000158038 2 233775679 MK0H2A maestro heat like repeats (BSource:HGNC Symbol;Acc:HGNC:24793] 30 ENSG00000157319 21 2558565 MRP139 mitochondrial ribosomal protein 139 [Source:HGNC Symbol;Acc:HGNC:2402] 27 ENSG00000175316 22 500897 MOV101 MoV101 MoV101 MoV101 MoV101 MoV101 20<	ENSG0000130383 ENSG00000181143 ENSG00000198453 ENSG00000268797 ENSG00000198633	19 19 19 19 19 19	5865826 8848844 36916329 40801297 52429187	FUT5 MUC16 ZNF568 AC008537.1 ZNF534	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337]	24 55 40 28 43
ENSG0000267265 19 S5006193 AC011476.3 novel transcript, antisense to RDH13 and GP6 26 ENSG0000223538 19 S5759014 RFPLAA ret finger protein like 4A [Source:HGNC Symbol/Acc:HGNC:45147] 56 ENSG0000215626 2 24076526 FAM2288 family wth sequence similarity 228 member 8 [Source:HGNC Symbol/Acc:HGNC:45147] 56 ENSG00000135076 2 97113153 ANKRD36 antlyrin repeat domain 36 [Source:HGNC Symbol/Acc:HGNC:24736] 21 ENSG0000158088 2 130191745 TUBA3E tubulin alpha 3e [Source:HGNC Symbol/Acc:HGNC:2705] 37 ENSG0000158088 20 1540144 AL049634.2 movel protein, SIRPD readthrough 29 ENSG000001580784 21 44497934 TSPEAR thrombospondin protein 139 [Source:HGNC Symbol/Acc:HGNC:14027] 27 ENSG00000145754 3 10026414 FANCD2 FA complementaling roup 2 [Source:HGNC Symbol/Acc:HGNC:2703] 20 ENSG0000014554 3 10026414 FANCD2 FA complementaling roup 2 [Source:HGNC Symbol/Acc:HGNC:3764] 30 ENSG00000145608 3 14246599	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797 ENSG0000198633 ENSG0000239998	19 19 19 19 19 19 19	5865826 8848844 36916329 40801297 52429187 54572920	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603]	24 55 40 28 43 55
ENSG0000223638 19 55759014 RFPLAA ret finger protein like AA [Source:HGNC Symbol,Acc:HGNC:16449] 32 ENSG0000223292 19 55759118 RFPLAAL ret finger protein like AA [Source:HGNC Symbol,Acc:HGNC:2476] 21 ENSG0000025292 19 55759118 RFPLAAL ret finger protein like AA [Source:HGNC Symbol,Acc:HGNC:2476] 21 ENSG00000152066 2 20705266 FAAV288 family with sequence similarity 228 member [Source:HGNC Symbol,Acc:HGNC:24736] 30 ENSG00000152086 2 130191745 TUBA3E tubulin alpha 3e [Source:HGNC Symbol,Acc:HGNC:27936] 30 ENSG00000152086 2 1330191745 TUBA3E mestro heat like repeat family member 2A [Source:HGNC Symbol,Acc:HGNC:27936] 30 ENSG00000152086 12 1540144 AL04954.2 novel protein, SIRPB1-SINP0 readthrough 29 ENSG0000015308 2 13525556 MRP139 mitochondrial ritosomal protein ISPD readthrough 29 ENSG0000017546 22 50698979 MOVIDL1 MovIDL like RSC complex RNA helicase 1 [Source:HGNC Symbol,Acc:HGNC:2458] 38 ENSG0000017546 3	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797 ENSG0000198633 ENSG0000239998 ENSG0000104974	19 19 19 19 19 19 19 19 19	5865826 8848844 36916329 40801297 52429187 54572920 54593582	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602]	24 55 40 28 43 55 25
ENSG0000229292 19 55769118 RFPL4AL1 ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] 56 ENSG0000219626 2 24076526 FAM2288 family with sequence similarity 228 member 8 [Source:HGNC Symbol;Acc:HGNC:24736] 21 ENSG00000152086 2 130191745 TUBA3E tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] 56 ENSG00000152086 2 130191745 TUBA3E tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] 37 ENSG00000152086 20 1540144 AL049634.2 movel protein, SIRPB1-SIRP readthrough 29 ENSG00000175894 21 244497893 TSPEAR thrombospondin type laminin G domain and EAR repeats [Source:HGNC:Symbol;Acc:HGNC:14027] 27 ENSG00000175894 21 04497893 TSPEAR thrombospondin type laminin G domain and EAR repeats [Source:HGNC:Symbol;Acc:HGNC:14027] 20 ENSG0000014554 3 10026414 FAC02 FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1476] 30 ENSG00000160808 3 41246599 ULK4 unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3245] 32 E	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797 ENSG0000198633 ENSG0000239998 ENSG0000104974	19 19 19 19 19 19 19 19 19	5865826 8848844 36916329 40801297 52429187 54572920 54593582	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602]	24 55 40 28 43 55 25
ENSG0000129626 2 24076526 FAM228B family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] 21 ENSG000015976 2 97113153 ANKR036 ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] 56 ENSG0000152086 2 130191745 TUBA3E tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:20755] 37 ENSG0000152086 2 23375579 MROH2A maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:14027] 29 ENSG00000157319 21 2558555 MRP139 mitcohondria rinbosomal protein, 139 [Source:HGNC Symbol;Acc:HGNC:14027] 27 ENSG00000173146 22 5058879 MOV101 MoV101 [K MS1C complex RNA helicas L [Source:HGNC Symbol;Acc:HGNC:268] 35 ENSG00000173146 22 5058879 MOV101 MoV101 [K MS1C complex RNA helicas L [Source:HGNC Symbol;Acc:HGNC:27831] 30 ENSG00000172139 3 11240898 SLCSC1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3847] 30 ENSG00000172139 3 17243873 NAALAD2 N-acetylated alph-almed actic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:28451] <	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797 ENSG0000198633 ENSG0000239998 ENSG0000104974 ENSG00000104972	19 19 19 19 19 19 19 19 19 19	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605]	24 55 40 28 43 55 25 25 54
ENSG0000135976 2 97113153 ANKRD36 ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] 56 ENSG00000152086 2 130191745 TUBA3E TUbBA3E TUBA3E TUBA3E TUBA3E TUBA3E Source:HGNC Symbol;Acc:HGNC:27056] 37 ENSG00000260861 20 1540144 AL049634.2 novel protein, SIRPB1-SIRP readthrough 29 ENSG00000260861 21 44497893 TSPEAR thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:14027] 27 ENSG0000017894 21 44497893 TSPEAR thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:14027] 20 ENSG00000144554 3 10026414 FANCD2 FA complementation group D [Source:HGNC Symbol;Acc:HGNC:3781] 30 ENSG00000144554 3 11026414 FANCD2 FA complementation group D [Source:HGNC Symbol;Acc:HGNC:3781] 30 ENSG00000144554 3 11026414 FANCD2 FA complementation group D [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG00000144554 3 11026414 FANCD2 FA complementation group D [So	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797 ENSG0000198633 ENSG0000239998 ENSG0000104974 ENSG0000104972 ENSG0000267265	19 19 19 19 19 19 19 19 19 19 19	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6	24 55 40 28 43 55 25 25 54 26
ENSG0000135976 2 97113153 ANKRD36 ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] 56 ENSG00000152086 2 130191745 TUBA3E TUbBA3E TUBA3E TUBA3E TUBA3E TUBA3E Source:HGNC Symbol;Acc:HGNC:27056] 37 ENSG00000260861 20 1540144 AL049634.2 novel protein, SIRPB1-SIRP readthrough 29 ENSG00000260861 21 44497893 TSPEAR thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:14027] 27 ENSG0000017894 21 44497893 TSPEAR thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:14027] 20 ENSG00000144554 3 10026414 FANCD2 FA complementation group D [Source:HGNC Symbol;Acc:HGNC:3781] 30 ENSG00000144554 3 11026414 FANCD2 FA complementation group D [Source:HGNC Symbol;Acc:HGNC:3781] 30 ENSG00000144554 3 11026414 FANCD2 FA complementation group D [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG00000144554 3 11026414 FANCD2 FA complementation group D [So	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG0000104972 ENSG0000267265 ENSG0000223638	19 19 19 19 19 19 19 19 19 19 19 19	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449]	24 55 40 28 43 55 25 25 54 26 32
ENSG0000152086 2 130191745 TUBA3E tubulin alpha 3e [source:HGNC Symbol;Acc:HGNC:20765] 37 ENSG0000155038 2 233775679 MR0H2A maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:27936] 30 ENSG0000175084 20 1540144 AL049634.2 novel protein, SIRPB1-SIRPD readthrough 29 ENSG0000175894 21 2585656 MRPL33 mitchondrial ribosomal protein 139 [Source:HGNC Symbol;Acc:HGNC:14027] 27 ENSG00000175894 21 44497893 TSPEAR thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1268] 35 ENSG00000173146 22 50089879 MOV1011 Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:1268] 38 ENSG0000018038 3 41246599 ULK4 unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:4710] 56 ENSG00000172139 3 112140988 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3807] 32 ENSG00000152492 3 10723843 ZBR zinc finger B-box domain containing S0 [Source:HGNC Symbol;Acc:HGNC:3807] 23 <t< td=""><td>ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG00000267265 ENSG00000223638 ENSG00000229292</td><td>19 19 19 19 19 19 19 19 19 19 19 19</td><td>5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147]</td><td>24 55 40 28 43 55 25 25 54 26 32 56</td></t<>	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG00000267265 ENSG00000223638 ENSG00000229292	19 19 19 19 19 19 19 19 19 19 19 19	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147]	24 55 40 28 43 55 25 25 54 26 32 56
ENSG0000185038 2 233775679 MROH2A maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:27936] 30 ENSG0000260661 20 1540144 AL049634.2 novel protein, SIRPB1-SIRPD readthrough 29 ENSG0000154719 21 25585656 MRP139 mitochondrial ribosomal protein 139 [Source:HGNC Symbol;Acc:HGNC:14027] 27 ENSG0000173146 22 50089879 MOV10L1 Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:1268] 35 ENSG0000173146 22 50089879 MOV10L1 Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3285] 38 ENSG0000144554 3 10026414 FANCD2 FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3851] 30 ENSG00001242516 3 75672300 LINC00560 long intergenic non-yotein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:34710] 56 ENSG0000172139 3 112140898 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:23219] 23 ENSG0000177694 3 167239843 ZBBX zinc finger 8-box domain containing [Source:HGNC Symbol;Acc:HGNC:38265] 32 </td <td>ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG0000104972 ENSG00000267265 ENSG0000223638 ENSG000022922 ENSG0000219626</td> <td>19 19 19 19 19 19 19 19 19 19 19 19 19 2</td> <td>5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526</td> <td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B</td> <td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736]</td> <td>24 55 40 28 43 55 25 54 26 32 26 32 56 21</td>	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG0000104972 ENSG00000267265 ENSG0000223638 ENSG000022922 ENSG0000219626	19 19 19 19 19 19 19 19 19 19 19 19 19 2	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736]	24 55 40 28 43 55 25 54 26 32 26 32 56 21
ENSG0000260861 20 1540144 AL049634.2 novel protein, SIRPB1-SIRPD readthrough 29 ENSG0000154719 21 25585656 MRP139 mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] 27 ENSG0000073146 22 50089879 MOV1011 Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:2160] 35 ENSG0000148554 3 10026414 FANCD2 FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:45784] 30 ENSG0000168038 3 41246599 ULK4 unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG0000172139 3 112140898 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:26245] 32 ENSG0000177594 3 167239843 ZB8X zinc finger 8-box domain containing [Source:HGNC Symbol;Acc:HGNC:26245] 32 ENSG000017594 3 19529085 CCDC50 coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:28219] 23 ENSG000017594 3 195746765 MUC20-071 MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:51807] 42 ENSG0000017594	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG00000223638 ENSG00000223638 ENSG00000229292 ENSG00000219626 ENSG00000135976	19 19 19 19 19 19 19 19 19 19 19 19 19 2 2 2	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079]	24 55 40 28 43 55 25 54 26 32 56 21 56
ENSG0000154719 21 25585656 MRPL39 mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] 27 ENSG0000075164 22 50089879 MOV10L1 Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:1268] 35 ENSG000073146 22 50089879 MOV10L1 Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:2701] 20 ENSG0000144554 3 10026414 FANCD2 FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:48710] 36 ENSG0000124556 3 75672300 LIIKC00960 long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG0000122139 3 112140898 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:31401] 50 ENSG00000177694 3 167239843 ZBBX zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] 23 ENSG00000177694 3 17438573 NAALADL2 N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] 23 ENSG00001242086 3 19558062 MUC20 CDC50 colled-coil domain containing 50 [Source	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG0000104972 ENSG0000229638 ENSG0000229292 ENSG0000219626 ENSG0000135976 ENSG0000152086	19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:20765]	24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 37
ENSG0000175894 21 44497893 TSPEAR thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1268] 35 ENSG0000073146 22 50089879 MOV10L1 Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:7201] 20 ENSG0000144554 3 10026414 FANCD2 FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3585] 38 ENSG0000144554 3 41246599 ULK4 unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG0000127139 3 112140898 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:34710] 50 ENSG0000177594 3 167239843 ZBBX zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] 23 ENSG0000172549 3 19329085 CCDC50 coled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3307] 42 ENSG0000145113 3 195766765 MUC4 mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:544] 33 ENSG0000145138 4 168356735 DDX60L DEXD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:2424] 33 <t< td=""><td>ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG000014974 ENSG000014972 ENSG00000223638 ENSG00000223638 ENSG0000022922 ENSG00000219626 ENSG0000135976 ENSG0000152086</td><td>19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2</td><td>5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:20765] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:27936]</td><td>24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 37</td></t<>	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG000014974 ENSG000014972 ENSG00000223638 ENSG00000223638 ENSG0000022922 ENSG00000219626 ENSG0000135976 ENSG0000152086	19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:20765] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:27936]	24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 37
ENSG0000073146 22 50089879 MOV10L1 Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:7201] 20 ENSG0000144554 3 10026414 FANCD2 FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3585] 38 ENSG0000168038 3 41246599 ULK4 unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG0000242516 3 75672300 LINC00960 long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG0000172139 3 112140898 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:2425] 32 ENSG00001569064 3 167239843 ZBBX zinc fingre B-box domain containing [Source:HGNC Symbol;Acc:HGNC:23219] 23 ENSG0000152492 3 191329085 CCDC50 colled-coll domain containing 50 [Source:HGNC Symbol;Acc:HGNC:33807] 42 ENSG0000145113 3 195746765 MUC4 mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:2424] 33 ENSG0000181381 4 102885048 SLC9B1 solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:2424] 33 <t< td=""><td>ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797 ENSG0000268797 ENSG0000198633 ENSG0000139998 ENSG0000104972 ENSG0000226265 ENSG0000229292 ENSG0000229292 ENSG0000219626 ENSG0000135976 ENSG0000152086 ENSG0000152086</td><td>19 19 19 19 19 19 19 19 19 19 19 19 19 2 2 2 2</td><td>5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:20765] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:27936]</td><td>24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 37 30</td></t<>	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797 ENSG0000268797 ENSG0000198633 ENSG0000139998 ENSG0000104972 ENSG0000226265 ENSG0000229292 ENSG0000229292 ENSG0000219626 ENSG0000135976 ENSG0000152086 ENSG0000152086	19 19 19 19 19 19 19 19 19 19 19 19 19 2 2 2 2	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:20765] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:27936]	24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 37 30
ENSG0000073146 22 50089879 MOV10L1 Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:7201] 20 ENSG0000144554 3 10026414 FANCD2 FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3585] 38 ENSG0000168038 3 41246599 ULK4 unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG0000242516 3 75672300 LINC00960 long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG0000172139 3 112140898 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:2425] 32 ENSG00001569064 3 167239843 ZBBX zinc fingre B-box domain containing [Source:HGNC Symbol;Acc:HGNC:23219] 23 ENSG0000152492 3 191329085 CCDC50 colled-coll domain containing 50 [Source:HGNC Symbol;Acc:HGNC:33807] 42 ENSG0000145113 3 195746765 MUC4 mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:2424] 33 ENSG0000181381 4 102885048 SLC9B1 solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:2424] 33 <t< td=""><td>ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797 ENSG0000198633 ENSG0000239998 ENSG0000104974 ENSG0000104974 ENSG0000223638 ENSG0000223638 ENSG0000219626 ENSG0000135976 ENSG0000152086 ENSG0000185038 ENSG0000185038</td><td>19 19 19 19 19 19 19 19 19 19 19 19 2 2 2 2</td><td>5865826 8848844 36916329 40801297 52429187 54572920 545593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:4747] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:20765] movel protein, SIRPB1-SIRPD readthrough</td><td>24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 37 30 29</td></t<>	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000268797 ENSG0000198633 ENSG0000239998 ENSG0000104974 ENSG0000104974 ENSG0000223638 ENSG0000223638 ENSG0000219626 ENSG0000135976 ENSG0000152086 ENSG0000185038 ENSG0000185038	19 19 19 19 19 19 19 19 19 19 19 19 2 2 2 2	5865826 8848844 36916329 40801297 52429187 54572920 545593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:4747] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:20765] movel protein, SIRPB1-SIRPD readthrough	24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 37 30 29
ENSG0000144554 3 10026414 FANCD2 FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3585] 38 ENSG0000168038 3 41246599 ULK4 unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:47874] 30 ENSG0000122139 3 112140898 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:31401] 50 ENSG0000169064 3 167239843 ZBBX zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:26245] 32 ENSG0000152492 3 174438573 NAALADL2 N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] 23 ENSG0000152492 3 19558062 MUC20-OT1 MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:3219] 23 ENSG0000154037 4 10285048 SLC981 solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:2424] 33 ENSG0000113492 5 34998101 AGX72 alanineglyoxylate aminotranscript [Source:HGNC Symbol;Acc:HGNC:2424] 33 ENSG0000113492 5 34998101 AGX72 alanineglyoxylate aminotranscript [Source:HGNC Symbol;Acc:HGNC:14412] 30	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG000012625 ENSG000022658 ENSG0000229292 ENSG00000219626 ENSG00000135976 ENSG0000152086 ENSG0000152086 ENSG000015038	19 19 19 19 19 19 19 19 19 19 19 20 21	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6149] ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027]	24 55 40 28 43 55 25 54 26 32 56 21 56 37 30 29 27
ENSG00000168038 3 41246599 ULK4 unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:15784] 30 ENSG0000242516 3 75672300 LINC00960 long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG0000172139 3 112140898 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:23401] 50 ENSG0000169064 3 167239843 ZBBX zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:26245] 32 ENSG000017694 3 174438573 NAALADL2 N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:23219] 23 ENSG0000152492 3 191329085 CCDC50 coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3807] 42 ENSG0000145113 3 195746765 MUC24 mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:24241] 33 ENSG00001164037 4 102885048 SLC9B1 Solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:24241] 33 ENSG00000113492 5 34998101 AGT2 alanine-glyoxylate aminiotransferase 2 [Source:HGNC Symbol;Acc:HGNC:14412]	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG00001267265 ENSG000022658 ENSG0000229292 ENSG00000129626 ENSG00000152086 ENSG00000152086 ENSG0000152086 ENSG0000152086	19 19 19 19 19 19 19 19 19 19 2	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC:29mbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1268]	24 55 40 28 43 55 25 54 26 32 56 32 56 21 56 37 30 29 27 35
ENSG0000242516 3 75672300 LINC00960 long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:48710] 56 ENSG0000172139 3 112140898 SLC9C1 solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:31401] 50 ENSG0000169064 3 167239843 ZBBX zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:26245] 32 ENSG000017694 3 174438573 NALADL2 N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:23219] 23 ENSG0000152492 3 191329085 CCDC50 colled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3807] 42 ENSG00001242086 3 195658062 MUC20-OT1 MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:53807] 42 ENSG0000145113 3 195746765 MUC4 mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:2424] 33 ENSG0000184037 4 102885048 SLC981 solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:2424] 33 ENSG0000113492 5 34998101 AGXT2 alanine-glyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:1412]	ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG0000126765 ENSG0000229292 ENSG00000129626 ENSG00000159766 ENSG0000152086 ENSG0000152086 ENSG0000154719 ENSG0000157894 ENSG00000175894	19 19 19 19 19 19 19 19 19 19 2	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC:29mbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:24073]	24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20
ENSG00001721393112140898SLC9C1solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:31401]50ENSG00001690643167239843ZBBXzinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:26245]32ENSG00001776943174438573NALADL2N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:23219]23ENSG00001524923191329085CCDC50coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:18111]38ENSG00002420863195658062MUC20-OT1MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:53807]42ENSG00001451133195746765MUC4mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:27514]49ENSG00001640374102885048SLC9B1solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:2424]33ENSG0000113492534998101AGXT2alanine-glyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:13278]21ENSG0000133710511204241EPB41L4Aerythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278]21ENSG0000026503629941260HLA-Amajor histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931]52ENSG0000261272631010474MUC22mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755]20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG000014974 ENSG0000104974 ENSG00001267265 ENSG000022656 ENSG0000226265 ENSG0000129292 ENSG0000129292 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152084 ENSG0000154719 ENSG0000017584 ENSG0000073146 ENSG0000014554	19 19 19 19 19 19 19 19 19 19 2 3	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:24736] novel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:120765] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:21701] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:21585]	24 55 40 28 43 55 25 54 26 32 56 32 56 31 56 37 30 29 27 35 20 38
ENSG00001690643167239843ZBBXzinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:26245]32ENSG00001776943174438573NALADL2N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:23219]23ENSG00001524923191329085CCDC50coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:18111]38ENSG00002420863195658062MUC20-OT1MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:53807]42ENSG00001451133195746765MUC4mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:7514]49ENSG00001640374102885048SLC9B1solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:24244]33ENSG0000113492534998101AGXT2alanine-glyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:13278]21ENSG00001337105112142441EPB41L4Aerythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278]21ENSG0000026503629941260HLA-Amajor histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931]52ENSG0000265072631010474MUC22mucin 22 [Source:HGNC Symbol;Acc:HGNC:3975]20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG000012972 ENSG000022658 ENSG000022922 ENSG0000135976 ENSG0000135086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000154719 ENSG00000154719 ENSG0000015474 ENSG00000168038	19 19 19 19 19 19 19 19 19 19 2 2 2 2 20 21 22 3 3	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA1 LILRA1 HLRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRVL39 TSPEAR MOV10L1 FANCD2 ULK4	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:24736] novel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:21701] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinsee 4 [Source:HGNC Symbol;Acc:HGNC:35784]	24 55 40 28 43 55 25 54 26 32 56 32 56 21 56 37 30 29 27 35 20 38 30
ENSG00001776943174438573NALADL2N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:23219]23ENSG00001524923191329085CCDC50coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:18111]38ENSG00002420863195658062MUC20-OT1MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:53807]42ENSG00001451133195746765MUC4mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:7514]49ENSG00001640374102885048SLC9B1solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:2424]33ENSG0000113492534998101AGXT2alanine-glyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:13278]21ENSG00001337105112142441EPB41L4Aerythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278]21ENSG000001337105148025683SPINK5serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:14412]42ENSG000026503629941260HLA-Amajor histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931]52ENSG0000261272631010474MUC22mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755]20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG000014974 ENSG0000104974 ENSG0000229998 ENSG000022927 ENSG000022638 ENSG0000219626 ENSG0000152086 ENSG00000260861 ENSG00000260861 ENSG0000027844 ENSG00000157894 ENSG0000014554 ENSG00000145038 ENSG00000145038 ENSG00000260861 ENSG00000154719 ENSG0000015474 ENSG00000144554 ENSG00000145038 ENSG00000144554 ENSG00000168038 ENSG00000144554	19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 2585656 44497893 50089879 10026414 41246599 75672300	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA1 LILRA1 HLRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:24736] novel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:24736] maitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:24736] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:1268] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:35784]	24 55 40 28 43 55 25 54 26 32 56 32 56 21 56 37 30 29 27 35 20 38 30 56
ENSG00001776943174438573NALADL2N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:23219]23ENSG00001524923191329085CCDC50coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:18111]38ENSG00002420863195658062MUC20-OT1MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:53807]42ENSG00001451133195746765MUC4mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:7514]49ENSG00001640374102885048SLC9B1solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:2424]33ENSG0000113492534998101AGXT2alanine-glyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:13278]21ENSG00001337105112142441EPB41L4Aerythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278]21ENSG000001337105148025683SPINK5serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:14412]42ENSG000026503629941260HLA-Amajor histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931]52ENSG0000261272631010474MUC22mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755]20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG000014974 ENSG0000104974 ENSG0000229998 ENSG000022927 ENSG000022638 ENSG0000219626 ENSG0000152086 ENSG00000260861 ENSG00000260861 ENSG0000027844 ENSG00000157894 ENSG0000014554 ENSG00000145038 ENSG00000145038 ENSG00000260861 ENSG00000154719 ENSG0000015474 ENSG00000144554 ENSG00000145038 ENSG00000144554 ENSG00000168038 ENSG00000144554	19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 2585656 44497893 50089879 10026414 41246599 75672300	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA1 LILRA1 HLRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:24736] novel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:24736] maitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:24736] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:1268] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:35784]	24 55 40 28 43 55 25 54 26 32 56 32 56 21 56 37 30 29 27 35 20 38 30 56
ENSG0000152492 3 191329085 CCDC50 coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:18111] 38 ENSG0000242086 3 195658062 MUC20-OT1 MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:53807] 42 ENSG0000145113 3 195746765 MUC4 mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:27514] 49 ENSG0000164037 4 102885048 SLC9B1 solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:24244] 33 ENSG0000181381 4 168356735 DDX60L DEXD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:14112] 30 ENSG0000113492 5 34998101 AGXT2 alanineglyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG0000129595 5 112142441 EPB41L4A erythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG00000133710 5 148025683 SPINK5 serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:1931] 42 ENSG000026503 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 5	ENSG0000130383 ENSG0000181143 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG000014974 ENSG0000104974 ENSG0000229998 ENSG0000226265 ENSG000022638 ENSG000022922 ENSG0000152086 ENSG00001520866 ENSG00000185038 ENSG00000154719 ENSG00000175894 ENSG000014554 ENSG0000168038 ENSG0000168038 ENSG000014554 ENSG0000124554 ENSG0000121516 ENSG000012139	19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 2585656 44497893 50089879 10026414 41246599 75672300 112140898	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6494] ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:24736] novel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:27936] novel protein Ise Gamain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:2120] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3784] long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:31401]	24 55 40 28 43 55 25 54 26 32 56 32 56 21 56 37 30 29 27 35 20 38 30 29 27 35 20 38 30 56 50
ENSG0000242086 3 195658062 MUC20-OT1 MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:53807] 42 ENSG0000145113 3 195746765 MUC4 mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:7514] 49 ENSG0000164037 4 102885048 SLC9B1 solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:24244] 33 ENSG0000181381 4 168356735 DDX60L DEXD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:24244] 34 ENSG0000113492 5 34998101 AGXT2 alanineglyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:1412] 30 ENSG0000129595 5 112142441 EPB41L4A erythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG0000133710 5 148025683 SPINK5 serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:1931] 42 ENSG000026503 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 52 ENSG0000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG000014974 ENSG000014972 ENSG0000227265 ENSG0000223638 ENSG0000229292 ENSG0000219626 ENSG0000152086 ENSG0000152086 ENSG00001520861 ENSG0000154719 ENSG0000154719 ENSG000015474 ENSG000015474 ENSG000015474 ENSG000015474 ENSG0000015474 ENSG000015474 ENSG000015474 ENSG000015474 ENSG0000015474 ENSG0000015474 ENSG0000015474 ENSG0000015474 ENSG0000015474 ENSG0000015474 ENSG0000015474 ENSG0000015474 ENSG0000015474 ENSG000015474 ENSG000015474 ENSG000015474 ENSG000014538	19 19 19 19 19 19 19 19 19 19 20 21 22 3 3 3 3 3 3 3	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 2585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRA1 FAC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC:Symbol;Acc:HGNC:24073] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:25784] long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:3784] long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:3401] zinto finger PB-box domain containing [Source:HGNC Symbol;Acc:HGNC:34027]	24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 37 30 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32
ENSG0000145113 3 195746765 MUC4 mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:7514] 49 ENSG0000164037 4 102885048 SLC9B1 solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:24244] 33 ENSG0000181381 4 168356735 DDX60L DEXD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:26429] 34 ENSG0000113492 5 34998101 AGXT2 alanineglyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG0000133710 5 112142441 EPB41L4A erythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG0000133710 5 148025683 SPINK5 serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:1940] 42 ENSG000026503 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 52 ENSG0000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG0000223638 ENSG0000223638 ENSG000015086 ENSG000015086 ENSG000015086 ENSG000015719 ENSG00000175894 ENSG00000144554 ENSG00000144554 ENSG00000168038 ENSG00000144554 ENSG00000144554 ENSG00000172139 ENSG00000172139 ENSG00000172139 ENSG00000172139 ENSG00000172139	19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 3	5865826 8848844 36916329 40801297 52429187 54572920 54572920 54572920 54572920 54572920 545793582 54617158 55006193 55759014 55759118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573	FUTS MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] novel protein like 4A [ISource:HGNC Symbol;Acc:HGNC:24736] mestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:24736] novel protein L39 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein like 4A [Source:HGNC Symbol;Acc:HGNC:24736] movel protein JSurce:HGNC Symbol;Acc:HGNC:27936] novel protein JSurce:HGNC Symbol;Acc:HGNC:27936] novel protein JSurce:HGNC Symbol;Acc:HGNC:24736] movel protein JSurce:HGNC Symbol;Acc:HGNC:27936] novel protein JSurce:HGNC Symbol;Acc:HGNC:24737] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1268] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3285] uc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3784] long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:31401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:31401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:26245] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:23219]	24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 21 56 21 56 21 56 21 56 21 56 21 56 21 56 21 56 21 56 21 56 21 56 37 30 29 27 35 20 38 30 55 55 25 25 56 21 21 56 21 21 56 21 21 56 21 21 56 21 21 56 21 21 26 26 37 30 29 27 30 29 27 35 20 30 29 27 35 20 30 29 27 35 20 35 30 29 27 35 30 29 27 35 30 20 35 35 30 29 20 35 35 20 35 35 30 20 35 30 20 35 35 30 20 35 35 30 20 35 35 30 20 35 35 30 20 35 35 35 30 20 35 35 30 20 35 35 20 35 35 20 35 35 20 35 35 20 35 20 35 35 20 30 35 30 30 30 30 30 30 30 30 30 30 30 30 30
ENSG0000164037 4 102885048 SLC9B1 solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:24244] 33 ENSG0000181381 4 168356735 DDX60L DEXD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:26429] 34 ENSG0000113492 5 34998101 AGXT2 alanineglyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:14412] 30 ENSG0000129595 5 112142441 EPB41L4A erythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG0000133710 5 148025683 SPINK5 serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:15464] 42 ENSG000026503 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 52 ENSG0000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG0000223638 ENSG0000223638 ENSG000015086 ENSG0000152086 ENSG0000175894 ENSG00000144554 ENSG00000144554 ENSG00000172139 ENSG00000172139 ENSG00000172139 ENSG0000017694 ENSG0000017694	19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 <td>5865826 8848844 36916329 40801297 52429187 54572920 54572920 54572920 54572920 545793582 54617158 55006193 55759014 55759118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085</td> <td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50</td> <td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6449] ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein 139 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein 139 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:217936] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:21078] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:2101] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3285] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3285] long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:3471] solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3471] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3421] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:32473] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3245] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:26245] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:31401] zinc finger B-box domain containing 50 [Source:HGNC Symbol;Acc:HGNC:31401]</td> <td>24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 21 56 37 30 29 27 35 20 38 30 56 56 50 32 20 38 30 56 50 32 32 32 33</td>	5865826 8848844 36916329 40801297 52429187 54572920 54572920 54572920 54572920 545793582 54617158 55006193 55759014 55759118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6449] ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein 139 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein 139 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:217936] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:21078] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:2101] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3285] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3285] long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:3471] solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3471] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3421] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:32473] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3245] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:26245] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:31401] zinc finger B-box domain containing 50 [Source:HGNC Symbol;Acc:HGNC:31401]	24 55 40 28 43 55 25 54 26 32 56 21 56 21 56 21 56 37 30 29 27 35 20 38 30 56 56 50 32 20 38 30 56 50 32 32 32 33
ENSG0000181381 4 168356735 DDX60L DExD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:26429] 34 ENSG0000113492 5 34998101 AGXT2 alanineglyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:14412] 30 ENSG0000129595 5 112142441 EPB41L4A erythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG0000133710 5 148025683 SPINK5 serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:15464] 42 ENSG000026503 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 52 ENSG0000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG000018453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104974 ENSG0000223638 ENSG0000229292 ENSG0000114526 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG000017894 ENSG000014554 ENSG000014554 ENSG00001242516 ENSG0000124251 ENSG0000172139 ENSG0000172139 ENSG0000172422 ENSG000017694 ENSG0000124254 ENSG0000172422 ENSG000017694 ENSG0000124292 ENSG0000124292 ENSG0000124292	19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 3	5865826 8848844 36916329 40801297 52429187 54572920 54572920 54573582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 2558565 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 195658062	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC20-OT1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein L39 [Source:HGNC Symbol;Acc:HGNC:24736] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:24736] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:24736] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:24736] family mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:24736] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:24736] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:24736] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3285] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3285] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3285] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3282] Mov20 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3285] Mov20 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3285] Mov20 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:32401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:32401] zinc finger B-b	24 55 40 28 43 55 25 54 26 32 56 21 56 37 30 29 27 35 20 29 27 35 20 38 30 56 50 32 20 38 30 56 50 32 23 38 42
ENSG0000113492 5 34998101 AGXT2 alanineglyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:14412] 30 ENSG0000129595 5 11214241 EPB41L4A erythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG0000133710 5 148025683 SPINK5 serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:15464] 42 ENSG0000205030 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 52 ENSG0000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104974 ENSG000014974 ENSG000023638 ENSG0000223638 ENSG0000219626 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000154719 ENSG0000154719 ENSG00000154719 ENSG00000175894 ENSG00000172139 ENSG0000172139 ENSG0000172139 ENSG0000177139 ENSG00000177694 ENSG0000017694 ENSG0000017694 ENSG00000154292 ENSG00000154292 ENSG00000154292 ENSG00000154513	19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 3	5865826 8848844 36916329 40801297 52429187 54572920 54572920 5457382 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 195658062 195746765	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A FPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC20-OT1 MUC4	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:2168] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:2201] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:2385] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3784] long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:34710] solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:31401] zinc finger 8-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:33219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:33407] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:33407]	24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 38 30 56 50 32 23 38 42 49
ENSG0000113492 5 34998101 AGXT2 alanineglyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:14412] 30 ENSG0000129595 5 11214241 EPB41L4A erythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG0000133710 5 148025683 SPINK5 serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:15464] 42 ENSG000026503 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 52 ENSG0000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104974 ENSG000014974 ENSG000023638 ENSG0000223638 ENSG0000219626 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000154719 ENSG0000154719 ENSG00000154719 ENSG00000175894 ENSG00000172139 ENSG0000172139 ENSG0000172139 ENSG0000177139 ENSG00000177694 ENSG0000017694 ENSG0000017694 ENSG00000154292 ENSG00000154292 ENSG00000154292 ENSG00000154513	19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 3	5865826 8848844 36916329 40801297 52429187 54572920 54572920 5457382 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 195658062 195746765	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A FPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC20-OT1 MUC4	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:2168] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:2201] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:2385] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3784] long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:34710] solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:31401] zinc finger 8-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:33219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:33407] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:33407]	24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 38 30 56 50 32 23 38 42 49
ENSG0000129595 5 11214241 EPB41L4A erythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278] 21 ENSG0000133710 5 148025683 SPINK5 serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:15464] 42 ENSG0000206503 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 52 ENSG0000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104974 ENSG0000104974 ENSG0000124972 ENSG0000223638 ENSG0000219626 ENSG0000129292 ENSG0000129292 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG00000152086 ENSG00000152086 ENSG00000154719 ENSG00000154719 ENSG0000017419 ENSG0000017419 ENSG00000144554 ENSG00000172139 ENSG00000172139 ENSG00000172139 ENSG00000177694 ENSG00000152492 ENSG00000154037 ENSG00000154037 ENSG00000154037	19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 3	5865826 8848844 36916329 40801297 52429187 54572920 54572920 54572920 54572920 54572920 5457382 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 195658062 195746765 102885048	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC20-OT1 MUC4 SLC9B1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:24079] mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3783] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3784] long intergenic non-protein coling RNA 960 [Source:HGNC Symbol;Acc:HGNC:3210] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3784] long inte	24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 38 30 56 50 38 30 56 50 32 23 38 42 49 33
ENSG00000133710 5 148025683 SPINK5 serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:15464] 42 ENSG0000206503 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 52 ENSG0000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG000018453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104972 ENSG0000124972 ENSG0000223638 ENSG0000229292 ENSG0000135976 ENSG0000135978 ENSG000014719 ENSG000014719 ENSG0000172139 ENSG0000172139 ENSG0000177694 ENSG000017694 ENSG000014037 ENSG000014037 ENSG000014037 ENSG000014037	19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 3	5865826 8848844 36916329 40801297 52429187 54572920 54572920 5457382 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 195658062 195746765 102885048 168356735	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC20-OT1 MUC4 SLC9B1 DDX60L	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:24036] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:24039] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3407] solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3407] N-acetylated alpha-linke inton goup D2 [Source:HGNC Symbol;Acc:HGNC:3263] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:32219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:32219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:32219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:32219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:32241] MUC20 overlapping tr	24 55 40 28 43 55 25 54 26 32 56 32 21 56 37 30 29 27 35 20 38 30 29 27 35 20 38 30 56 50 38 30 56 50 32 23 38 42 49 33 34
ENSG0000206503 6 29941260 HLA-A major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] 52 ENSG0000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG0000126755 ENSG000022656 ENSG0000229292 ENSG0000219626 ENSG0000129026 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000154719 ENSG0000154719 ENSG0000154719 ENSG0000144554 ENSG0000144554 ENSG0000172139 ENSG0000152086 ENSG0000177694 ENSG000001242516 ENSG00000152082 ENSG00000152082 ENSG00000152081 ENSG00000152082 ENSG00000152081 ENSG00000152082 ENSG00000152083 ENSG00000152084 ENSG00000152082 ENSG00000152082 ENSG00000152082	19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 3	5865826 8848844 36916329 40801297 52429187 54572920 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 195658062 195746765 102885048 168356735 34998101	FUTS MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRA1 FAM288 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC20-0T1 MUC4 SLC981 DDX60L AGXT2	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein like 4A liso 1 [Source:HGNC Symbol;Acc:HGNC:24079] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:34731] long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:3470] solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3471] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3421] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3221] Accetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3221] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3221] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3243] DExD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:3244] DEXD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:2542] alanineglyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:2424]	24 55 40 28 43 55 25 54 26 32 56 32 21 56 37 30 29 27 35 20 38 30 29 27 35 20 38 30 56 50 38 30 56 50 32 23 38 42 49 33 44 30
ENSG00000261272 6 31010474 MUC22 mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755] 20	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104972 ENSG00001267265 ENSG0000229292 ENSG0000219626 ENSG0000129626 ENSG00001290286 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152088 ENSG0000152088 ENSG0000152084 ENSG0000154719 ENSG0000154719 ENSG0000144554 ENSG00001242516 ENSG00001242516 ENSG00001242516 ENSG00001242086 ENSG0000152492 ENSG00001242086 ENSG00001242086 ENSG0000143131 ENSG000013492 ENSG000013492 ENSG000013492 ENSG000013492 ENSG00001242555	19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 3	5865826 8848844 36916329 40801297 52429187 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 195746765 102885048 168356735 34998101 112142441	FUTS MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 ULRA1 FAM288 AC011476.3 RFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9B1 DDX60L AGXT2 EPB41L4A	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16447] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:1268] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:1268] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:1268] Mov10 like RiSC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:3210] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3210] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3210] solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3210] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3210] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3210] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3210] coiled-coil domain containing S0 [Source:HGNC Symbol;Acc:HGNC:3210] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:3210] DEXD/H-box 60 like [Source:HGNC S	24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 37 30 29 27 35 20 38 30 56 50 38 30 56 50 32 23 38 42 49 33 34 43 00 21
	ENSG0000130383 ENSG0000130383 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104972 ENSG00001267265 ENSG0000229292 ENSG0000219626 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG00000152086 ENSG00000154719 ENSG00000144554 ENSG00000144554 ENSG0000152492 ENSG00000152492 ENSG00000152492 ENSG00000152492 ENSG0000015493 ENSG0000013492 ENSG000013492 ENSG000013492 ENSG000013492 ENSG0000013492 ENSG0000013492	19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 2 3 <tr< td=""><td>5865826 8848844 36916329 40801297 52429187 54572920 54572920 5457382 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 179438573 191329085 195658062 195746765 102885048 168356735 34998101 112142441 148025683</td><td>FUTS MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRA1 FAM28 AC011476.3 RFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9B1 DDX60L AGXT2 EPB41L4A SPINK5</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:16473] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1268] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:23219] solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3219] fA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing S0 [Source:HGNC Symbol;Acc:HGNC:3214] solute carrier family 9 member 81 [Source:HGNC Symbol;Acc:HGNC:3214] solute carrier family 9 member 81 [Source:HGNC Symbol;Acc:HGNC:3244] DEXD/H-box 60 like [Source:HGNC S</td><td>24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 20 38 30 56 50 32 38 30 56 32 33 38 30 56 50 32 32 33 38 42 49 33 34 30 21 42</td></tr<>	5865826 8848844 36916329 40801297 52429187 54572920 54572920 5457382 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 179438573 191329085 195658062 195746765 102885048 168356735 34998101 112142441 148025683	FUTS MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRA1 FAM28 AC011476.3 RFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9B1 DDX60L AGXT2 EPB41L4A SPINK5	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:16449] ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:16473] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24736] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1268] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:23219] solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3219] fA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing S0 [Source:HGNC Symbol;Acc:HGNC:3214] solute carrier family 9 member 81 [Source:HGNC Symbol;Acc:HGNC:3214] solute carrier family 9 member 81 [Source:HGNC Symbol;Acc:HGNC:3244] DEXD/H-box 60 like [Source:HGNC S	24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 20 38 30 56 50 32 38 30 56 32 33 38 30 56 50 32 32 33 38 42 49 33 34 30 21 42
	ENSG0000130383 ENSG0000130383 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104972 ENSG000012972 ENSG000022922 ENSG000022922 ENSG0000152086 ENSG0000152087 ENSG0000147549 ENSG0000144554 ENSG0000142513 ENSG000016064 ENSG0000145133 ENSG0000145133 ENSG0000145133 ENSG0000145133 ENSG0000133710 ENSG0000133710 ENSG0000133710 ENSG0000133710 ENSG0000133710	19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 2 3 <tr< td=""><td>5865826 8848844 36916329 40801297 52429187 54572920 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 195658062 195746765 102885048 168356735 34998101 112142441 148025683 29941260</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 ILLRA1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9R1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:645147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB-I-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1278] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipetidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3219] mucin 4, cell s</td><td>24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 38 30 56 50 32 33 38 30 56 50 32 33 38 42 49 33 34 42 49 33 34 42 52</td></tr<>	5865826 8848844 36916329 40801297 52429187 54572920 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 195658062 195746765 102885048 168356735 34998101 112142441 148025683 29941260	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 ILLRA1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9R1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:645147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB-I-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1278] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipetidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3219] mucin 4, cell s	24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 38 30 56 50 32 33 38 30 56 50 32 33 38 42 49 33 34 42 49 33 34 42 52
EIN3GUUUUU2U4330 0 31142439 CCHCKI COIIEG-COII alpha-helical rod protein 1 [Source:HGNC Symbol;Acc:HGNC:I3930] 33	ENSG0000130383 ENSG0000130383 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104972 ENSG0000126765 ENSG000022922 ENSG000022922 ENSG0000152086 ENSG0000154719 ENSG0000154719 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144513 ENSG0000145413 ENSG00001454131 ENSG00001454133 ENSG000013492 ENSG000013492 ENSG000013492 <tr< td=""><td>19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 2 3 <tr< td=""><td>5865826 8848844 36916329 40801297 52429187 54572920 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 195658062 195746765 102885048 168356735 34998101 112142441 148025683 29941260</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 ILLRA1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9R1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:645147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB-I-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1278] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipetidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3219] mucin 4, cell s</td><td>24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 38 30 56 50 32 33 38 30 56 50 32 33 38 42 49 33 34 42 49 33 34 42 52</td></tr<></td></tr<>	19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 2 3 <tr< td=""><td>5865826 8848844 36916329 40801297 52429187 54572920 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 195658062 195746765 102885048 168356735 34998101 112142441 148025683 29941260</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 ILLRA1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9R1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:645147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB-I-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1278] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipetidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3219] mucin 4, cell s</td><td>24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 38 30 56 50 32 33 38 30 56 50 32 33 38 42 49 33 34 42 49 33 34 42 52</td></tr<>	5865826 8848844 36916329 40801297 52429187 54572920 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 195658062 195746765 102885048 168356735 34998101 112142441 148025683 29941260	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 ILLRA1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9R1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:645147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB-I-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1278] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipetidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3219] mucin 4, cell s	24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 38 30 56 50 32 33 38 30 56 50 32 33 38 42 49 33 34 42 49 33 34 42 52
ENSG0000204525 6 31268749 HLA-C major histocompatibility complex, class I, C [Source:HGNC.Symbol;Acc:HGNC:4933] 58	ENSG0000130383 ENSG0000130383 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104974 ENSG0000104972 ENSG0000126765 ENSG000022922 ENSG000022922 ENSG0000152086 ENSG0000154719 ENSG0000154719 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144554 ENSG0000144513 ENSG0000145413 ENSG00001454131 ENSG00001454133 ENSG000013492 ENSG000013492 ENSG000013492 <tr< td=""><td>19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 2 3 <tr< td=""><td>5865826 8848844 36916329 40801297 52429187 54572920 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 195658062 195746765 102885048 168356735 34998101 112142441 148025683 29941260</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 ILLRA1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9R1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:645147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB-I-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1278] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipetidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3219] mucin 4, cell s</td><td>24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 38 30 56 50 32 33 38 30 56 50 32 33 38 42 49 33 34 42 49 33 34 42 52</td></tr<></td></tr<>	19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 2 2 2 2 3 <tr< td=""><td>5865826 8848844 36916329 40801297 52429187 54572920 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 195658062 195746765 102885048 168356735 34998101 112142441 148025683 29941260</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 ILLRA1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9R1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:645147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB-I-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1278] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipetidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3219] mucin 4, cell s</td><td>24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 38 30 56 50 32 33 38 30 56 50 32 33 38 42 49 33 34 42 49 33 34 42 52</td></tr<>	5865826 8848844 36916329 40801297 52429187 54572920 54572920 54593582 54617158 55006193 55759014 55769118 24076526 97113153 130191745 233775679 1540144 25585656 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 195658062 195746765 102885048 168356735 34998101 112142441 148025683 29941260	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 ILLRA1 AC011476.3 RFPL4A RFPL4AL1 FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC4 SLC9R1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:645147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] novel protein, SIRPB-I-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1278] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:14027] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1401] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] N-acetylated alpha-linked acidic dipetidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:3219] mucin 4, cell s	24 55 40 28 43 55 25 54 26 32 56 32 56 37 30 29 27 35 20 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 38 30 56 50 32 33 38 30 56 50 32 33 38 42 49 33 34 42 49 33 34 42 52
	ENSG0000130383 ENSG0000130383 ENSG0000198453 ENSG0000198453 ENSG0000198453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104974 ENSG0000104972 ENSG0000223638 ENSG0000223638 ENSG000015086 ENSG000015086 ENSG0000152086 ENSG00000175149 ENSG00000175149 ENSG00000175139 ENSG00000175139 ENSG000001752492 ENSG00000145113 ENSG00000124295 ENSG0000012428 ENSG00000124295 ENSG00000124955 ENSG00000124595 ENSG00000124595 ENSG00000124595 ENSG00000124595 ENSG00000124595	19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 3 5 5	5865826 8848844 36916329 40801297 52429187 54572920 54572920 545793582 54617158 55006193 55759014 55759118 24076526 97113153 130191745 233775679 1540144 2558565 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 19558062 195746765 102885048 168356735 34998101 112142441 148025683 29941260 31010474 31142439	FUTS MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRA1 LILRA1 LILRA1 SRFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC20-OT1 MUC4 SLC981 DDX600 AGXT2 EPB41L4A SPINK5 HLA-A MUC22 CCHCR1	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 554 [Source:HGNC Symbol;Acc:HGNC:26337] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:45147] maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:24736] novel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1203] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:14027] thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1203] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1203] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:1301] zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:3401] wice-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3401] zinc finger F-box domain containing [Source:HGNC Symbol;Acc:HGNC:3424] DEXD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:3424] Distore framily 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3424] Distore framily 9 member B1 [Source:HGNC Symbol;Acc:HGNC:3424] Distore framily 9 member B1 [Source:HGNC Symbol;Acc:HGNC:3424] Distore framily 9 member 21 [Source:HGNC Symbol;Acc:HGNC:3424] DEXD/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:3424] Distore framily 9 member 21 [Source:HGNC Symbol;Acc:HGNC:3424] Distore framily 9 member B1 [Source:HGNC Symbol;Acc:HG	24 55 40 28 43 55 25 25 26 32 56 21 56 21 56 37 30 29 27 35 20 38 30 29 27 35 20 38 30 56 50 32 20 38 30 56 50 32 20 38 30 36 50 32 38 30 30 56 50 32 23 38 30 32 23 38 30 22 33 38 42 49 33 34 42 52 20 33
ENSG0000234745 6 31353872 HLA-B major histocompatibility complex, class I, B [Source:HGNC Symbol;Acc:HGNC:4932] 58	ENSG0000130383 ENSG0000130383 ENSG0000181143 ENSG000018453 ENSG0000198633 ENSG0000198633 ENSG0000198633 ENSG0000104972 ENSG0000239998 ENSG0000223638 ENSG0000223638 ENSG0000219626 ENSG0000219626 ENSG0000219626 ENSG0000219626 ENSG000015086 ENSG000015086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000152086 ENSG0000175894 ENSG0000175894 ENSG0000124516 ENSG00001242516 ENSG0000177594 ENSG0000177694 ENSG0000124292 ENSG000013710 ENSG000013310 ENSG000013310 ENSG000013310 ENSG000013310 ENSG0000124525 ENSG000024526 ENSG000013310	19 19 19 19 19 19 19 19 19 19 19 2 2 2 2 2 2 2 2 2 3 <tr< td=""><td>5865826 8848844 36916329 40801297 52429187 54572920 54572920 54572920 54572920 54572920 54572920 545793582 54617158 5506193 55759014 55759118 24076526 97113153 130191745 233775679 1540144 2558565 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 19558062 195746765 102885048 168356735 34998101 112142441 148025683 29941260 31010474 31142439 31268749</td><td>FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC20-OT1 MUC4 SLC9B1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A MUC22 CCHCR1 HLA-C</td><td>fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:1582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:603] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:46147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:2703] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:2168] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:23585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3263] Noact arrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3243] Nacetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:32219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:32219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3307] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:3307] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:3307] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:3327] bolute carrier family 9 member 21 [Source:HGNC Symbol;Acc:HGNC:3327] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:3307] mucin 4, cell sur</td><td>24 55 40 28 43 55 25 54 26 32 56 21 56 37 30 29 27 35 20 29 27 35 20 38 30 56 50 32 20 38 30 56 50 32 20 38 30 56 50 32 23 38 42 49 33 34 42 49 52 20 33 34 55 52 20 33 35 52 52 20 33 35 55 52 52 52 52 52 52 52 52 52 53 55 56 56 50 56 56 56 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 56 56 57 56 56 57 56 56 57 56 56 56 56 56 50 56 56 56 56 56 56 56 56 56 56 56 56 56</td></tr<>	5865826 8848844 36916329 40801297 52429187 54572920 54572920 54572920 54572920 54572920 54572920 545793582 54617158 5506193 55759014 55759118 24076526 97113153 130191745 233775679 1540144 2558565 44497893 50089879 10026414 41246599 75672300 112140898 167239843 174438573 191329085 19558062 195746765 102885048 168356735 34998101 112142441 148025683 29941260 31010474 31142439 31268749	FUT5 MUC16 ZNF568 AC008537.1 ZNF534 LILRA2 LILRA1 LILRB1 AC011476.3 RFPL4A FAM228B ANKRD36 TUBA3E MROH2A AL049634.2 MRPL39 TSPEAR MOV10L1 FANCD2 ULK4 LINC00960 SLC9C1 ZBBX NAALADL2 CCDC50 MUC20-OT1 MUC4 SLC9B1 DDX60L AGXT2 EPB41L4A SPINK5 HLA-A MUC22 CCHCR1 HLA-C	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016] mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:1582] zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392] novel protein zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:603] leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6602] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6603] leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6605] novel transcript, antisense to RDH13 and GP6 ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:46147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:45147] family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736] ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:24079] tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:27936] movel protein, SIRPB1-SIRPD readthrough mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:2703] FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:2168] Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:23585] unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:3263] Noact arrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:3243] Nacetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:3219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:32219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:32219] coiled-coil domain containing [Source:HGNC Symbol;Acc:HGNC:3307] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:3307] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:3307] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:3327] bolute carrier family 9 member 21 [Source:HGNC Symbol;Acc:HGNC:3327] mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:3307] mucin 4, cell sur	24 55 40 28 43 55 25 54 26 32 56 21 56 37 30 29 27 35 20 29 27 35 20 38 30 56 50 32 20 38 30 56 50 32 20 38 30 56 50 32 23 38 42 49 33 34 42 49 52 20 33 34 55 52 20 33 35 52 52 20 33 35 55 52 52 52 52 52 52 52 52 52 53 55 56 56 50 56 56 56 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 57 56 56 56 56 57 56 56 57 56 56 57 56 56 56 56 56 50 56 56 56 56 56 56 56 56 56 56 56 56 56

Gil J. et al. | Malignant melanoma proteogenomics

·		1			1
ENSG00000204520	6	31399784	MICA	MHC class I polypeptide-related sequence A [Source:HGNC Symbol;Acc:HGNC:7090]	25
ENSG00000168477	6	32041153	TNXB	tenascin XB [Source:HGNC Symbol;Acc:HGNC:11976]	23
ENSG00000225914	6	32254640	TSBP1-AS1	TSBP1 and BTNL2 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:39756]	29
ENSG00000198502	6	32517353	HLA-DRB5	major histocompatibility complex, class II, DR beta 5 [Source:HGNC Symbol;Acc:HGNC:4953]	53
ENSG00000196126	6	32578769	HLA-DRB1	major histocompatibility complex, class II, DR beta 1 [Source:HGNC Symbol;Acc:HGNC:4948]	60
ENSG00000196735	6	32628179	HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1 [Source:HGNC Symbol;Acc:HGNC:4942]	53
ENSG00000179344	6	32659467	HLA-DQB1	major histocompatibility complex, class II, DQ beta 1 [Source:HGNC Symbol;Acc:HGNC:4944]	59
ENSG00000237541	6	32741391	HLA-DQA2	major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC Symbol;Acc:HGNC:4943]	43
ENSG00000232629	6	32756098	HLA-DQB2	major histocompatibility complex, class II, DQ beta 2 [Source:HGNC Symbol;Acc:HGNC:4945]	35
ENSG00000231389	6	33064569	HLA-DPA1	major histocompatibility complex, class II, DP alpha 1 [Source:HGNC Symbol;Acc:HGNC:4938]	24
ENSG00000176381	6	166305300	PRR18	proline rich 18 [Source:HGNC Symbol;Acc:HGNC:28574]	24
ENSG00000146733	7	56011051	PSPH	phosphoserine phosphatase [Source:HGNC Symbol;Acc:HGNC:9577]	25
ENSG00000205277	7	100969623	MUC12	mucin 12, cell surface associated [Source:HGNC Symbol;Acc:HGNC:7510]	57
ENSG00000204983	7	142749468	PRSS1	serine protease 1 [Source:HGNC Symbol;Acc:HGNC:9475]	48
ENSG00000177710	8	11331012	SLC35G5	solute carrier family 35 member G5 [Source:HGNC Symbol;Acc:HGNC:15546]	20
ENSG00000145002	8	12425614	FAM86B2	family with sequence similarity 86 member B2 [Source:HGNC Symbol;Acc:HGNC:32222]	25
ENSG00000104763	8	18055992	ASAH1	N-acylsphingosine amidohydrolase 1 [Source:HGNC Symbol;Acc:HGNC:735]	20
ENSG00000253125	8	22690150	AC055854.1	novel transcript	20
ENSG0000070756	8	100685816	PABPC1	poly(A) binding protein cytoplasmic 1 [Source:HGNC Symbol;Acc:HGNC:8554]	56
ENSG00000156795	8	123416726	NTAQ1	N-terminal glutamine amidase 1 [Source:HGNC Symbol;Acc:HGNC:25490]	21
ENSG0000044459	9	17134982	CNTLN	centlein [Source:HGNC Symbol;Acc:HGNC:23432]	25
ENSG0000010438	9	33750679	PRSS3	serine protease 3 [Source:HGNC Symbol;Acc:HGNC:9486]	51
ENSG00000137054	9	37485948	POLR1E	RNA polymerase I subunit E [Source:HGNC Symbol;Acc:HGNC:17631]	23
ENSG00000106772	9	76611376	PRUNE2	prune homolog 2 with BCH domain [Source:HGNC Symbol;Acc:HGNC:25209]	25
ENSG00000277556	9	104598457	OR13C5	olfactory receptor family 13 subfamily C member 5 [Source:HGNC Symbol;Acc:HGNC:15100]	27
ENSG00000165181	9	111686173	SHOC1	shortage in chiasmata 1 [Source:HGNC Symbol;Acc:HGNC:26535]	23
ENSG00000122136	9	135546126	OBP2A	odorant binding protein 2A [Source:HGNC Symbol;Acc:HGNC:23380]	20
ENSG0000005022	NA	119468422	SLC25A5	solute carrier family 25 member 5 [Source:HGNC Symbol;Acc:HGNC:10991]	59
ENSG00000147274	NA	136848004	RBMX	RNA binding motif protein X-linked [Source: HGNC Symbol;Acc:HGNC:9910]	40

Table S4. Summary statistics showing the average number of somatic and germline mutations in 16 KEGG pathways known to be dysregulated in melanoma. The pathways were selected our proteomic data and previous knowledge.

No. of genes in the pathway	No. of genes detected in WES data	KEGGID	Pathway	Number of somatic mutations	Number of germline mutations
133	105	hsa00190	Oxidative phosphorylation	202 ± 52	17 ± 4
51	45	hsa00330	Arginine and proline metabolism	187 ± 45	21 ± 4
48	46	hsa00280	Valine, leucine and isoleucine degradation	146 ± 41	20 ± 3
57	47	hsa00480	Glutathione metabolism	153 ± 38	11 ± 3
151	123	hsa03040	Spliceosome	485 ± 117	26 ± 7
98	88	hsa03015	mRNA surveillance pathway	422 ± 98	56 ± 10
46	42	hsa03050	Proteasome	120 ± 31	12 ± 4
294	276	hsa04010	MAPK signaling pathway	1568 ± 313	118 ± 13
240	214	hsa04020	Calcium signaling pathway	1578 ± 300	179 ± 14
354	317	hsa04151	PI3K-Akt signaling pathway	1932 ± 383	222 ± 17
120	109	hsa04152	AMPK signaling pathway	634 ± 131	48 ± 7
166	158	hsa04310	Wnt signaling pathway	832 ± 170	55 ± 6
67	52	hsa00010	Glycolysis / Gluconeogenesis	218 ± 54	28 ± 5
140	131	hsa04120	Ubiquitin mediated proteolysis	701 ± 179	45 ± 6
79	75	hsa03018	RNA degradation	315 ± 79	55 ± 11
109	95	hsa04066	HIF-1 signaling pathway	494 ± 112	35 ± 6